 
Main Office • 7240 ACC Blvd  • Raleigh, NC 27617  
 
  
Clinical Study Protocol  
 
 
Study Title:  Efficacy of Centanafadine  SR as a potential smoking 
cessation treatment  
Protocol Number:   Protocol # 405- 201- 00055  
Compound:    Centanafadine Sustained release Tablets (EB -1020) 
IND Number:  155242  
Sponsor:  Otsuka Pharmaceutical  
Development & Commercialization, Inc.  
2440 Research Boulevard  
Rockville, Maryland 20850, United States  
IRE Contact:  Rose Research Center  
 
Email:  
Phone:  
V
ersion Number:    Version 3.0 – Amendment 1  
Version Date:    August 16, 2021 
Principal Investigator:   
Medical Supervisio n:   
Protocol Authors:   
 
 
  
Data and information contained in this document are considered to constitute trade secrets and confidential 
commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly 
disclosed without the written consent of the Rose Research Center, LLC.   Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
1
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 2 of 66 
TABLE OF CONTENTS  
Appendix  ....................................................................................................................................................... 6  
Figures  ........................................................................................................................................................... 7  
Tables  ............................................................................................................................................................ 7  
Explanation of Terms  .................................................................................................................................... 7  
Abbreviations  ................................................................................................................................................ 8  
Summary of Changes  .................................................................................................................................. 11 
Amendment 1 – Protocol Version 3.0 – 16 Aug 2021  ............................................................................. 11 
Synopsis  ...................................................................................................................................................... 12 
 Introduction ........................................................................................................................................ 14 
1.1 Background  ................................................................................................................................. 14 
1.2 Study Rational e ........................................................................................................................... 15 
 Study Objectives and Endpoints  ......................................................................................................... 15 
2.1 Primary Objective: Smoking Abstinence  ..................................................................................... 15 
2.1
.1 Endpoints  ............................................................................................................................ 15 
2.2 Secondary Objective: Reduction in Incidence of Nausea  ........................................................... 15 
2.2.1  Endpoint  .............................................................................................................................. 15 
 Investigational Plan  ............................................................................................................................. 16 
3.1 Overall Study Design and Plan .................................................................................................... 16 
3.2 Study and S
ession Durations  ....................................................................................................... 16 
 Participant Involvement  ...................................................................................................................... 16 
4.1 Point of Enrollment  ..................................................................................................................... 16 
4.2 Inclusion Criteria  ......................................................................................................................... 17 
4.3 Exclu
sion Criteria  ......................................................................................................................... 17 
4.3.1  Participants of Childbearing Potential (CBP)  ....................................................................... 18 
4.4 Recruitment Strategies  ............................................................................................................... 19 
4.4.1  Pre-Screening ...................................................................................................................... 19 
4.5 Participant Retention in the Study  .............................................................................................. 19 
4.6 Discontinuation of Participants from Study  ................................................................................ 19 
4.7 Lost to Follow -up ........................................................................................................................ 20 
4.8 Violation of Inclusion/Exclusion Criteria  ..................................................................................... 20 
4.9 Session and Response Windows  ................................................................................................. 20 Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
2
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 3 of 66 
4.9.1  V2 Session Window  ............................................................................................................. 20 
4.9.2  V3 Session Window  ............................................................................................................. 20 
4.9.3  All other visit Windows  ....................................................................................................... 20 
4.9.4  Daily Message Response Window  ...................................................................................... 20 
 Investigational Medicinal Product (IMP)  ............................................................................................ 20 
5.1 Centanafadine SR (EB- 1020)  ....................................................................................................... 20 
5.1.1 Packaging and Labeling  ....................................................................................................... 21 
5.2 Dosing Regimen  .......................................................................................................................... 21 
5.2.1  Dosing Rationale  ................................................................................................................. 21 
5.2.2  Dose  Adjustment Procedures  ............................................................................................. 21 
5.3 Storage and Accountability  ......................................................................................................... 21 
5.3.1  Storage  ................................................................................................................................ 21 
5.3.2  Accountability  ..................................................................................................................... 22 
5.3.3  Destruction  .......................................................................................................................... 22 
5.4 Product Quality Complaints  ........................................................................................................ 22 
5.4.1  Eliciting and Reporting a PQC  ............................................................................................. 22 
5.4.2  Information Required for Reporting Purposes  ................................................................... 22 
5.4.3  Return Process for Complaint Sample  ................................................................................ 23 
5.4.4  Assessment and Evaluation  ................................................................................................ 23 
 Study Procedures and Activities  ......................................................................................................... 23 
6.1 Informed Consent and Guidance  ................................................................................................ 23 
6.2 Virtual Scre
ening Procedures  ...................................................................................................... 23 
6.3 Sampling for Future Biospecimen Research (FBR)  ...................................................................... 24 
6.4 Samplings for Pharmacokinetics (PK) .......................................................................................... 24 
6.5 Safety Evaluations and Other Assessments  ................................................................................ 24 
6.5.1  Clinical Chemistry  ................................................................................................................ 25 
6.5.2  Hematology  ......................................................................................................................... 25 
6.5.3  Serum Pregnancy Test ......................................................................................................... 25 
6.5.4  Urinalysis  ............................................................................................................................. 25 
6.5.5  Urine Drug Screen  ............................................................................................................... 25 
6.5.6  Urine Pregnancy Test  .......................................................................................................... 26 
6.5.7  Electrocardiogram (ECG)  ..................................................................................................... 26 
6.5.8  Vital Signs  ............................................................................................................................ 26 Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
3
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 4 of 66 
6.5.9  Physical Examination  ........................................................................................................... 26 
6.5.10  Expired Air CO Breath Test  .................................................................................................. 26 
6.5.11  Medical History and Concomitant Disease  ......................................................................... 26 
6.5.12  Prior and Concomitant Medication  ..................................................................................... 27 
6.5.13  Body Height and Body Weight  ............................................................................................ 27 
6.5.14  Demographics  ..................................................................................................................... 27 
6.5.15  AE/SAE Reporting ................................................................................................................ 27 
6.5.16  Questionnaires  .................................................................................................................... 27 
6.6 Visit Procedures  .......................................................................................................................... 29 
6.6.1  Screening (V1)  ..................................................................................................................... 29 
6.6.2  Baseline (V2) – Day -1 ......................................................................................................... 29 
6.6.3  Day before Quit Day (V3) – 1 week on IMP  ........................................................................ 30 
6.6.4  Visit 4 (V4) – 3 weeks on IMP  .............................................................................................. 31 
6.6.5  Visit 5 (V5) – 5 weeks on IMP  .............................................................................................. 31 
6.6.6  Final Study Visit (V6) – 7 weeks on IMP  .............................................................................. 32 
6.6.7  Telephone Contact  .............................................................................................................. 33 
6.6.8  Safety Follow -Up ................................................................................................................. 33 
6.7 Daily Messaging  .......................................................................................................................... 33 
6.7.1  Daily Message (after screening, prior to V2)  ...................................................................... 33 
6.7.2  Daily Message (Visit 2 through V6)  ..................................................................................... 33 
6.8 Schedule of Events  ...................................................................................................................... 34 
 Risk / Benefit Information  ................................................................................................................... 35 
7.1 Potential Benefits  ........................................................................................................................ 35 
7.2 Import ance of Knowledge to be Gained  ..................................................................................... 35 
7.3 Potential Risks  ............................................................................................................................. 35 
7.3.1  Centanafadine SR  ................................................................................................................ 35 
7.3.2  Tobacco Withdrawal  ........................................................................................................... 35 
7.3.3  Blood Draw  .......................................................................................................................... 35 
7.4 Concomitant Medications  ........................................................................................................... 35 
7.5 Protection Against Risks  .............................................................................................................. 36 
7.5.1  Blood Pressure Monitoring  ................................................................................................. 36 
 Quality Control and Quality Assurance  ............................................................................................... 36 
8.1 Monitoring Activities  ................................................................................................................... 36 Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
4
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 5 of 66 
8.1.1  Site Initiation Visit (SIV)  ....................................................................................................... 36 
8.1.2  Interim Monitoring Visits (IMVs)  ........................................................................................ 37 
8.1.3  Close -Out Visit (COV)  .......................................................................................................... 37 
8.2 Training of Staff  ........................................................................................................................... 37 
8.3 Audits and Inspections  ................................................................................................................ 37 
 Adverse Events  .................................................................................................................................... 37 
9.1 Definitions  ................................................................................................................................... 37 
9.1.1  Adverse Even t (AE)  .............................................................................................................. 37 
9.1.2  Serious Adverse Event (SAE) ............................................................................................... 38 
9.1.3  Nonserious Adverse Event  .................................................................................................. 38 
9.1.4  Immediately Reportable Event (IRE)  ................................................................................... 38 
9.1.5  Psychiatric Adverse Events .................................................................................................. 38 
9.1.6  Changes in Clinical Laboratory Test Values  ......................................................................... 39 
9.2 Collection of Safety Events from Participants  ............................................................................. 39 
9.2.1  Period of Collection  ............................................................................................................. 39 
9.3 Assessment of Adverse Events  ................................................................................................... 40 
9.3.1  Severity of Adverse Events  .................................................................................................. 40 
9.3.2  IMP Causality  ....................................................................................................................... 40 
9.4 Immediately Reportable Events  .................................................................................................. 40 
9.5 Adverse Events of Special Interest  .............................................................................................. 40 
9.6 Abuse Potential Monitoring Plan  ................................................................................................ 41 
9.7 Potential Serious Hepatotoxicity  ................................................................................................ 41 
9.8 Pregnancy after Enrollment  ........................................................................................................ 41 
9.9 Follow -up of Non -serious Adverse Events  .................................................................................. 42 
9.10  Follow -up of Serious Adverse Events and Immediately Reportable Events  ............................... 42 
9.11  Follow -up and Repor ting of Serious Adverse Events and Immediately Reportable Events 
Occurring after Last Scheduled Contact  ................................................................................................. 43 
 Data Management  .............................................................................................................................. 43 
10.1  Data Collection Procedures  ......................................................................................................... 43 
10.2  Protocol Deviations
 / Noncompliance  ........................................................................................ 43 
10.3  Data Capture  ............................................................................................................................... 43 
10.3.1  Pre-screening Data  .............................................................................................................. 44 
10.3.2  At-home Dat a Collection  ..................................................................................................... 44 Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
5
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 6 of 66 
10.3.3  Electronic Data Capture System .......................................................................................... 44 
10.4  Missing Data  ................................................................................................................................ 44 
10.5  Data Handling  .............................................................................................................................. 44 
10.6  Data Validation ............................................................................................................................ 44 
10.7  Database Lock  ............................................................................................................................. 44 
 Planned Statistical Methods  ............................................................................................................... 45 
11.1  Sample Size Estimation  ............................................................................................................... 45 
11.2  Statistical Methods  ..................................................................................................................... 45 
11.3  Outcomes  .................................................................................................................................... 45 
11.3.1  Smoking Abstinence  ............................................................................................................ 45 
11.3.2  Incidence of Nausea  ............................................................................................................ 45 
 Ethics and Regulations  ........................................................................................................................ 46 
12.1  IRB Approval  ................................................................................................................................ 46 
12.2  Investigational New Drug A
pplication  ........................................................................................ 46 
12.3  GCP and Regulatory Requirements  ............................................................................................. 46 
12.4  Participant Information and Consent  ......................................................................................... 46 
12.5  Amendment to Informed Consent Form  .................................................................................... 46 
 Administrative Considerations  ............................................................................................................ 47 
13.1  Participant Confidentiality  .......................................................................................................... 47 
13.2  Records Retention  ....................................................................................................................... 47 
13.2.1  Fi
le Management at the Trial Site  ....................................................................................... 47 
13.2.2  Records Retention at the Trial Site  ..................................................................................... 47 
13.3  Publication Authorship Requirements  ........................................................................................ 47 
 References  .......................................................................................................................................... 49 
 
APPENDIX  
Appendix 1 - Columbia- Suicide Severity Rating Scale (C -SSRS), "Screening" and "Since Last Visit"  ........... 52 
Appendix 2 – Fagerström Test for Nicotine Dependence (FTND)  ............................................................... 58 
Appendix 3 – Smoking History  .................................................................................................................... 59 
Appendix 4 – Other Nicotine Use Questionnaire ........................................................................................ 60 
Appendix 5 – Modified Cigarette Evaluation Questionnaire – Extended (mCEQE)  .................................... 61 
Appendix 6 – Reasons to Smoke  ................................................................................................................. 63 
Appendix 7 – Shiffman Jarvik Withdrawal Scale  ......................................................................................... 64 Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
6
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 7 of 66 
Appendix 8 – Minnesota Nicotine Withdrawal Scale  ................................................................................. 66 
FIGURES  
Figure 1 - Overall Study Design and Plan, 7 -Week Treatment Period  ........................................................ 16 
 
TABLES  
Table 1 - Clinical Chemistry  ......................................................................................................................... 25 
Table 2 - Hematology  .................................................................................................................................. 25 
Table 3 - Serum Pregnancy  ......................................................................................................................... 25 
Table 4 - Urinalysis  ...................................................................................................................................... 25 
Table 5 - Drug Screening  ............................................................................................................................. 26 
Table 6 - Schedule of Event  ......................................................................................................................... 34 
EXPLANATION OF TERMS  
The following special terms are used in this protocol:  
Baseline Visit  The baseline visit for this study is defined a V2.  
Baseline Value  The baseline value is defined as the value at V2 unless otherwise specified.  
End of Study  The end of study (EOS) for a subject is defined as the date of safety follow -up 
or the date of early termination of the subject.  
Combustible cigarette  The term ‘combustible cigarette’ (CC) refers to commercially available, 
combustible cigarettes and excludes hand -rolled cigarettes , cigars, pipes, 
bidis, and other nicotine containing products.  
Volunteer  A volunteer is an individual who has expressed interest in participating in a 
clinical research study.  
Candidate  Individual s who completed a pre -screening evaluation with a member of the 
Rose Research Center recruitment team. They have been deemed as pre-
qualified to come in for a physical screening visit to determine further 
eligibility.  
Participant  A volunteer who has signed  the study consent form. Once an individual signs 
the study consent form and receives a participant number, they are considered a Participant. The term “Subject” can and has historically been used interchangeably with Participant but for the purposes of communication, RRC has adopted the term participant as a global term for 
this status.  
 
  Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
7
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 8 of 66 
ABBREVIATIONS  
5-HT Serotonin  
ADHD  Attention -deficit/hyperactivity disorder  
AE Adverse event  
AESI  Adverse event of special interest  
ALT Alanine aminotransferase  
AP Alkaline phosphatase  
APMP  Abuse Potential Monitoring Process  
AST Aspartate aminotransferase  
BID Twice daily  
BL Baseline  
BMI Body mass index  
BUN  Urea nitrogen  
CBP Childbearing potential  
CC Combustible  cigarette  
CFR Code of Federal Regulations  
CO Carbon monoxide  
CRF Case report form  
C-SSRS  Columbia -Suicide Severity Rating Scale  
DA Dopamine  
DNA  Deoxyribonucleic acid  
ECG Electrocardiogram  
eCRF  Electronic case report form  
EOS End of Study  
FBR Future biospecimen research  
FDA Food and Drug Administration  
ESAM  Events Subject to Additional Monitoring  
FTND  Fagerström test for nicotine dependence  Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
8
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 9 of 66 
GCP Good Clinical Practice  
HBA1c  Hemoglobin  A1c 
HCG  Human chorionic gonadotropin  
ICF Informed consent form  
ICH International Conference on Harmonisation  
IMP Investigational Medicinal Product  
IND Investigational New Drug  
IRB Institutional Review Board  
IRE Immediately Reportable Event  
kg Kilograms  
Lbs pounds  
MAOI  Monoamine Oxidase Inhibitor  
mCEQ  Modified Cigarette Evaluation Questionnaire.  
MCH  Mean corpuscular hemoglobin  
MCHC  Mean corpuscular hemoglobin concentration  
MCV  Mean corpuscular volume  
mg Milligram  
MHI  Medication handling irregularit y 
mL Milliliter  
MNWS  Minnesota Nicotine Withdrawal Scale  
NE Norepinephrine  
OPDC  Otsuka Pharmaceutical Development & Commercialization, Inc.  
PPM  Parts per million  
PQC  Product Quality Complain  
QTc Corrected QT interval  
RBC Red blood cell  
RCT Randomized Control Trial  
RNA  Ribonucleic acid  Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
9
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 10 of 66 
RRC Rose Research Center, LLC.  
SaaS  Software -as-a-Service  
SAE Serious adverse event  
SMS  Short Message Service  
SNRI  Selective Norepinephrine Reuptake Inhibitor  
SOP Standard operating procedure  
SR Sustained Release  
SSL Secure Sockets Layer  
SSRI  Selective Serotonin Reuptake Inhibitor  
TCA Tricyclic Antidepressant  
TDD  Total daily dose  
TLS Transport Layer Security  
WBC  White blood cell 
WHO  World Health Organization  
 
  Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
10
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 11 of 66 
SUMMARY OF CHANGES  
AMENDMENT 1 – PROTOCOL VERSION 3.0 – 16 AUG 2021  
• Clarification of “smoking cessation treatments” in Exclusion #14.  
• Clarification of exclusionary medications in Exclusion #7 . 
• The PHQ -9 has been replaced  with the C-SSRS  based on recommendations from the FDA.  
Section 9.1.5  Psychiatric Adverse Events  was added . 
• Additional questionnaire added to assess use of other forms of nicotine  between study visits.  
• Clarification of laboratory tests ordered to properly characterize non -traumatic lesions.  (Section 
9.5 – Adver se Events of Special Interest ) 
  Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
11
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 12 of 66 
SYNOPSIS  
SPONSOR  
Otsuka Pharmaceutical  
Development & Commercialization, Inc.  
2440 Research Boulevard  
Rockville, Maryland 20850, United States  
INVESTIGATIONAL PRODUCT  
Centanafadine Sustained release Tablets (EB- 1020)  
STUDY TITLE 
Efficacy of centanafadine SR as a potential smoking cessation treatment   
PROTOCOL NUMBER  
405-201-00055 
EXECUTIVE SUMMARY  
This single -group, open -label study of 50 subjects will explore the potential of centanafadine in 
promoting smoking abstinence in adult smokers seeking to quit. The efficacy and tolerability of 
centanafadine at a dose of 400 mg total daily dose ( TDD ) (200 mg twice daily [BID]) approximately 4 to 6 
hours apart (during a 7- week treatment period) will be compared with a benchmark of abstinence based 
on historical data from clinical trials of varenicline, viewed as the most efficacious pharmacotherapy currently approved by the FDA.  
OBJECTIVES  AND ENDPOINTS  
The primary endpoint is the four -week continuous abstinence rate of subjects with the treatment of 
centanafadine during weeks 4 -7. A participant is considered abstinent from combustible cigarettes if he 
or she self- reports tobacco abstinence (no cigarette smoking, not even a puff) assessed by responses to 
daily messages throughout the period and has an exhaled carbon monoxide (CO) level of less than 5 
ppm using the Vitalograph BreathCO monitor in the office at Visit 5 and Visit 6.  
A secondary objective will be to determine if centanafadine yields equivalent efficacy to that of varenicline, with a significant reduction in the incidence of nausea the most prevalent side effect 
reported following varenicline treatment.  Incidence rate of nausea is assessed by self -reported side 
effects collected via an open- ended question at each study visit.  
STUDY DESIGN  
This single -group, small- scale, open -label study (N= 50) will evaluate centanafadine SR (400 TDD ) as a 
pote ntial smoking cessation treatment. Participants enrolled in the study will be given centanafadine SR 
at a dose of 400 mg TDD (200 mg BID) approximately 4 to 6 hours apart for seven  weeks.  Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
12
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 13 of 66 
The study will consist of up to a 28 -day screening period, a baseline visit, a 7-week treatment period, 
and a 7 -day safety follow -up period.  
  
DOSING RATIONALE  
The 400 mg TDD of centanafadine SR oral tablets (200 mg BID) will be evaluated in this study.  This dose 
was found to produce a significant blockade (>10%) of transporters for serotonin, dopamine, and 
norepinephrine as well as alleviating symptoms of inattention and hyperactivity/impulsivity in patients with ADHD, without inducing a high incidence of nausea and headache that occur with doses as high as 
800 mg.
1   
SAMPLE SIZE ESTIMATION  
Given the conditional logic of the phase one analyses, Monte Carlo simulations based on a sample size 
of 50 were conducted to determine the significance thresholds for the binomial tests so that the overall 
Type I error rate across all tests would be 10% (9.87% of 100,000 simulated datasets) , assuming the null 
hypothesis that centanafadine yields a  four -week continuous smoking abstinence rate of 50% and an 
overall incidence of nausea of 30% . The power of the phase one analyses (probability of moving to 
phase two) was also determined by Monte Carlo simulations for three scenarios.  In the first scenario, 
the treatment has a higher four -week continuous abstinence  rate at 6 week s post target quit date (65%) 
than varenicline, but an equivalent rate of nausea (30%). Power under this scenario  is about 74% . In the 
second scenario, the treatment has the same four -week continuous abstinence rate at 6 week s post 
target quit date as varenicline (50%) but has a lower nausea rate (15%). Power under this scenario  is 
about 76%. Last, if the treatment generates both a higher four -week continuous abstinence rate at 6 
week s post target quit date (65%) and a lower rate of nausea (1 5%) then power  is about 94%.  
STATISTICAL METHODS  
The estimation of the four -week continuous smoking abstinence rate at 6 weeks post target quit date is 
around 50% and 30% of treated individuals experiencing nausea from varenicline treatment based on 
the hi storical studies.2 The smoking abstinence rate during weeks 4 -7 will be calculated with 90% 
binomial confidence intervals, and the incidence rate of nausea will be tabulated, which will be compared with the thresholds established for efficacy and tolerability.    SCR
Screeni ng 
Peri odWK1 WK4V1V2 V6
(± 3 days) (+ 2 days)7-Week Treatment Period
V4
(± 3 days)V5
(± 3 days)V3 Phone 
Call 1 Week IMP
Base line (+ 3 days)Day -1
Day 1 
First dose IMP3 Weeks IMP 5 Weeks IMP 7 Weeks IMP
Last dose IMP7-Day Safety 
Follow-up
Target 
Quit DayWK8 WK7 WK2 WK3 WK5 WK6
Centanafadine SR 400 mg TDD
(200 mg BID)Centanafadine 
SR 400 mg TDD
(200 mg BID)Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
13
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 14 of 66 
 INTRODUCTIO N 
1.1 BACKGROUN D 
Cigarette smoking remains the leading cause of preventable death in the United States , and is one of the 
leading causes of preventable morbidity and mortality.3,4 An esti mated 540,000 smokers die each year 
from smoking -related diseases.5 Existing treatments for tobacco cessation yield, on average, less than 
25% long -term abstinence rates, with many of the cessation failures occurring within the first month of 
abstinence.6 There is an urgent need to develop new therapies for smoking cessation.7 Current 
pharmacological approaches  are efficacious for s moking cessation, but continue to have poor long- term 
abstinence rates, with potentially concerning adverse events.  
There are currently seven Food and Drug Administration ( FDA)-approved smoking cessation 
medications, which fall into three main categories: nicotine replacement therapy (NRT) including 
nicotine patch, gum, lozenge, inhaler, and nasal spray; varenicline (Chantix); and bupropion 
(Zyban/Wellbutrin). Among US smokers, 29.1% use NRT when attempting to quit smoking whereas only 7.9% use varenicline and 2.4% use bupropion .
8,9 Two other medications that show some efficacy, 
clonidine and nortryptyline, are not FDA approved, and account for less than 1% of smoking cessation 
treatment.10 None of the current treatments yields sustained abstinence rates of over 25% at one year, 
but varenicline is the most efficacious. Varenicline is a full agonist on α7 -nicotinic acetylcholine 
receptors (nAChRs) and a partial agonist on the α4β2, α3β4, and α6β2 subtypes.2,11,12 Smoking 
abstinence rates at weeks 9 -12 in two Phase III trials of varenicline were nearly identical at 44%. Given 
that four -week continuous abstinence at weeks 4 -7 will be taken to be the primary abstinence outcome 
in the present study, and modeling relapse curves over the initial weeks of abstinence suggests that 
abstinence rates are ~5% higher at 6 weeks than at 12 weeks after the target quit -smoking date,13 in this 
study a slightly higher rate of 50% abstinence will be taken to be the benchmark criterion to meet or 
exceed.  Common a dverse events associated with varenicline include nausea, insomnia, abnormal 
dreams, headaches, and nasopharyngitis.14 The most common adverse reaction reported is nausea, with 
30-40% of participants in randomized control trials reporting mild to moderate levels of nausea.15 
Discontinuation/drop -out rates of nearly 10% have been noted during clinical trials due to these adverse 
effects.16 In real- world settings, discontinuation of varenicline treatment may be as high as 57%.8 
Nicotine inhaled from cigarette smoke reaches the br ain rapidly17 and acts on nicotinic acetylcholine 
receptors to release several neurotransmitters involved in arousal, attention and mood regulation. 
Among these are the monoamines dopamine, norepinephrine and serotonin .18,19 When dependent 
smokers abstain from smoking, nicotine withdrawal symptoms are experienced, including difficulty 
concentrating, irritability, and depressed mood,20 which are thought to be due in part to a deficit in 
monoamine neurotransmitter activity. Centanafadine is a triple monoamine transporter inhibitor that acts to block re -uptake of norepinephrine , dopamine and seroton in (half- maximal inhibitory 
concentration [IC
50] 6 nM), dopamine (IC 50 38 nM), and serotonin (IC 50 83 nM) ,21 and thus may 
counteract the withdrawal -induced deficit in these neurotransmitters accompanying smoking cessation. 
Indeed, bupropion, which is an efficacio us smoking cessation treatment, is thought to exert its 
therapeutic actions by inhibiting re -uptake of dopamine and norepinephrine .
 Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
14
CCI
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 15 of 66 
 
 A
dditionally , smoking relapse is 
hypothesized to result in part from impulsivity, which has been shown to be reduced by centanafadine 
treatment.1 
1.2 STUDY RATIONAL E 
Smokers that go through nicotine withdrawal often experience difficulty concentrating, hypoarousal, and negative mood,  which could be alleviated by centanafadine’s effect in enhancing monoamine 
neurotransmitter activity.  
This trial will explore the potential of centanafadine in promoting smoking abstinence in adult smokers seeking to quit. The efficacy and tolerability of centanafadine at a dose of 400 mg per day will be 
compared with a benchmark of abstinence based on historical data from clinical trials of varenicline, 
viewed as the most efficacious pharmacotherapy currently approved by the FDA.  
This single -group, open -label study of 50 participants  will evaluate oral administration of c entanafadine 
sustained -release tablets (EB- 1020), to help smokers abstain from smoking combustible cigarettes 
during a 7- week study period.  
 STUDY OBJECTIVE S AND ENDPOINTS  
2.1 PRIMARY OBJECTIVE : SMOKING ABSTINENCE  
The primary objective will be to determine whether centanafadine yields a superior four- week 
continuous smoking ab stinence rate compared to varenicline during weeks 4 -7. Abstinence will be 
defined as self-report of no cigarette smoking (not even a puff), confirmed by an expired air CO reading 
of less than 5 ppm at week 7 . 
2.1.1 Endpoint s 
• Self-report of no cigarette smoking (not even a puff) , assessed by response s on daily 
message s.  
• Expired air CO reading of less than 5 ppm , assessed in office using the Vitalograph BreathCO 
monitor.  
2.2 SECONDARY OBJECTIVE : REDUCTION IN INCIDENCE OF NAUSEA  
A secondary objective will be to determine if centanafadine yields equivalent efficacy to that of varenicline), with a significant reduction in the incidence of nausea, the most prevalent side effect 
reported following varenicline treatment.  
2.2.1 Endpoint  
Self-report of side effects  assessed b y open -ended question at each study visit.  Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
15
CCI
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 16 of 66 
 INVESTIGATIONAL PLAN 
3.1 OVERALL STUDY DESIGN AND PLAN 
This single -group, small- scale, open -label, phase 2 study (N= 50) will evaluate centanafadine as a 
potential smoking cessation treatment. The dose of centanafadine SR that will be evaluated in this trial 
will be 400 mg TDD (200 mg BID) approximately 4 to 6 hours apart for seven  weeks.  
The study will consist of a 14 -day screening period, a baseline visit, a 7- week treatment period, and a 7 -
day safety follow -up period. Participants will visit the study center a total of six times, including a 
screening visit (V1), baseline visit (V2), a v isit one week (+ 3 days) after starting the study drug (V3), 
three weeks  (± 3 days) after starting the study drug (V4), five  weeks (± 3 days) after starting the study 
drug (V5), and seven  weeks (± 3 days) after starting the study drug (V6). All participants will be 
requested to participate in a 7 -day safety follow up period, which will consist of telephone contact seven  
days (+2  days ) after the last dose of investigational product.  
  
Figure 1 - Overall Study Design and Plan, 7 -Week Treatment Period  
3.2 STUDY AND SESSION DURATIONS  
The total duration for a participant  will be approximately 10 weeks . The Screening S ession (Visit 1)  will 
last approximately 2 ½ to 3 hours . The other study sessions will last approximately 1 to 1 ½ hours.  
 PARTICIPANT INVOLVEMENT  
The study population will include fifty (50) cigarette smoking adults, between  21 and 65 years  of age, 
inclusive , with no restriction on gender, race and ethnicities, or social- economic status, who have 
smoked an average of at least 10 commercially available cigarettes per day for the last 12  months . 
4.1 POINT OF ENROLLMENT  
Participants will be enrolled at V2 , after all safety laboratory results have been received and reviewed  by 
the medical staff (MD or PA).  SCR
Day 1 
First dose IMP3 Weeks IMP 5 Weeks IMP 7 Weeks IMP
Last dose IMPV1V6
(± 3 days) (+ 2 days)7-Week Treatment Period
V4
(± 3 days)V5
(± 3 days)V3 Phone 
Call 1 Week IMPV2
Base line (+ 3 days)Day -1
7-Day Safety 
Follow-up
Target 
Quit DayWK8 WK7 WK2 WK3 WK5 WK6
Centanafadine SR 400 mg TDD
(200 mg BID)Centanafadine 
SR 400 mg TDD
(200 mg BID)Screeni ng 
Peri odWK1 WK4Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
16
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 17 of 66 
4.2 INCLUSION CRITERIA  
Inclusion Criteria  
1.  Has signed the ICF and is able to read and understand the information provided in the ICF.  
2.  Smokers 21 to 65 years of age (inclusive) at screening.  
3.  Smokes an average of at least 10 commercially available cigarettes per day for the last 12 months.  
4.  Has an expired air CO reading of at least 10 ppm at screening.  
5.  At screening, e xpress a desire to quit smoking within the next 30 days.  
6.  BMI of 18 to 40 kg/m2, inclusive at screening.  
7.  Willing and able to comply with the requirements of the study.  
8.  Owns a smart phone with text message and data capabilities compatible with necessary surveys.  
4.3 EXCLUSION CRITERIA  
Exclusion Criteria  
1.  Participants  of childbearing potential ( CBP) who are breast -feeding and/or have a positive pregnancy 
test result . 
2.  Participant  presenting with, or having a history of, uncontrolled hypertension (systolic blood pressure > 
150 mmHg or diastolic blood pressure > 9 5 mmHg) or symptomatic hypotension . 
3.  Participants with known ischemic heart disease or history of myocardial infarction, congestive heart 
failure (whether controlled or uncontrolled), angioplasty, stenting, coronary artery bypass surgery, or 
other serious cardiac problems that would place him/her at increased vulnerability to the 
sympathomimetic effects of a stimulant medication.  
4.  History of seizures (after the age of 17 years) . 
5.  Participants  of CBP or sexually active participants  unless they agree to practice 2 different methods of 
birth control or remain abstinent during the course of the trial and for 30 days after the last dose of 
Investigation Medicinal Product ( IMP) for participants of CBP , and 30 days after the last dose of IMP for 
participants  with partners who are of CBP . Unless the participant  is sterile ( i.e., participants  who have 
had a bilateral oophorectomy or hysterectomy or who have been postmenopausal for at least 12 consecutive months; or participants  who have had a bilateral orchidectomy) or remains abstinent, 2 of 
the following precautions must be used: vasectomy, tubal ligation, vaginal diaphragm, intrauterine device, birth control pills, birth control injection, birth control implant, birth control patch, condom 
with spermicide, or sponge with spermicide. Participants who do not agree to refrain from donating 
sper m from screening through 30  days after the last dose of IMP.  
6.  Participant  has a history of dermatologic adverse reactions secondary to any drug exposure  or any 
active/uncontrolled dermatologic disease.  
7.  Currently t aking antidepressants  (e.g., SSRI’s SNRI’s, TCA’s or MAOI’s) , antipsychotics  (such as 
butyrophenones, thioxanthines, atypical antipsychotics or other heterocyclics ), benzodiazepines, 
hypnotics , or medications that prolong QTc . MAOI’s  taken within 30 days of screening.  
8.  Screening  (Visit 1)  or Baseline (Visit 2)  C-SSRS  score greater than 0 (any answer “Yes”) for the SUICIDAL 
IDEATION  section or greater than 0 for the SUICIDAL BEHAVIOR  section (any answer “Yes”)   
9.  Substance use disorder within 12 months prior to screening.  
10.  Participants  that have a positive alcohol test (via breathalyzer or blood), a positive drug screen for illicit 
drugs ( Table 6.3.5) at screening or baseline.   
NOTE: Participants  who test positive for marijuana at screening may be enrolled if they have no 
evidence of a substance use disorder  and if they agree to refrain from use for the duration of the trial . 
11.  Any participant  who has any other medical or physical condition(s) that, in the opinion of the 
investigator, may prevent the participant  from completing the trial or would go against the 
participant’s  best interest with participation in the trial. This would include any significant illness or 
unstable medical condition that could lead to difficulty complying with the protocol.  Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
17
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 18 of 66 
Exclusion Criteria  
12.  The following laboratory test and ECG results are exclusionary:  
1) Platelets ≤ 75,000/mm3 
2) Hemoglobin ≤ 9 g/dL  
3) Neutrophils, absolute ≤ 1000/mm3 
4) AST > 2 × upper limit of normal  
5) ALT > 2 × upper limit of normal  
6) Creatinine ≥ 2 mg/dL  
7) HbA1c ≥ 7%  
8) QTcF > 450 msec for males or > 470 msec for females  
 
NOTE: In addition, participants  should be excluded if they have any other abnormal laboratory tests, 
vital sign results, or ECG findings which in the investigator’s judgment are medically significant and  that 
would impact the safety of the participant  or the interpretation of the trial results . 
13.  Participants  with a history of prior exposure to centanafadine.  
14.  Use of smokeless tobacco (chewing tobacco, snuff), cigars (except for “Black & Mild” cigars or 
Cigarillos), pipes, hookah, e- cigarettes , nicotine replacement therapy or other smoking cessation 
treatments (e.g., bupropion as Zyban, or varenicline)  within 14 days of screening.  
15.  Participants  who participated in a clinical trial and were exposed to interventional trial medication 
within the last 30 days prior to screening or who participated in more than 2 interventional clinical 
trials within the past year.  
ALT = alanine aminotransferase; AST = aspartate aminotransferase; CBP = childbearing potential; HbA1c = 
glycosylated hemoglobin; QTcF = QT interval corrected for heart rate by the Fridericia formula.  
4.3.1 Participants  of Childbearing Potential  (CBP)  
Participants of CBP  are defined as participants  for whom menstruation has started and who are not 
documented as sterile (ie, hav e had a bilateral oophorectomy and/or hysterectomy or who have been 
postmenopausal for at least 12 consecutive months).  
For participants of CBP and for participants  who are sexually active, there must be a documented 
agreement that the participant  and/or t heir partner will take effective measures ( i.e., double -barrier 
method) to prevent pregnancy during the course of the trial and for 30 days after the last dose of IMP. 
Unless the participant  is sterile ( i.e., females who have had a bilateral oophorectomy and/or 
hysterectomy or who have been postmenopausal for at least 12 consecutive months; or males who have 
had a bilateral orchidectomy) or remains abstinent, 2 of the following precautions must be used: vasect omy, tubal ligation, vaginal diaphragm, intrauterine device, birth control pills, birth control 
injection, birth control implant, birth control patch, condom with spermicide, or sponge with spermicide. Any single method of birth control, including vasectom y and tubal ligation, may fail, leading 
to pregnancy. The contraceptive method will be documented at each trial visit. Male participants  must 
also agree not to donate sperm from screening through 3 0 days after the last dose of IMP.  
Before trial enrollment,  participants of CBP must be advised of the importance of avoiding pregnancy 
during trial participation and the potential risk factors for an unintentional pregnancy. The participant  
must sign an informed consent form stating that the above -mentioned  risk factors and the 
consequences were discussed with her.  
A serum pregnancy test (screening visit only) or urine pregnancy test (all other visits) for human chorionic gonadotropin will be performed on participants  who have the potential  to become pregnant . 
If a urine test is performed and is positive, the investigator will follow up with a confirmatory serum test.  Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
18
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 19 of 66 
4.4 RECRUITMENT  STRATEGIES  
 
 
 
 
 
 
 
 
 
 
 
  
4.4.1 Pre-Screening  
Pre-screening will be completed prior to V1 for all participant s. Participants will be provided with a set of 
IRB approved questions directly related to the inclusion and exclusion criteria. Based upon the outcome 
of these questions, potential participants may be scheduled for a screening visit (V1).  
4.5 PARTICIPANT  RETENTION  IN THE STUDY  
All candidates who schedule a screening visit (V1) will receive a series of email, text, and telephone 
reminders; participants are also permitted through these com munications to confirm, cancel, or 
reschedule all their appointments.  
4.6 DISCONTINUATION  OF PARTICIPANT S FROM STUDY  
Discontinued participant s will include both participant s who withdraw from the study ( participant ’s 
decision) or participant s who are discontinued from the study (following Investigator’s decision). A 
participant  can only be discontinued from the study after the IMP is dispensed to them . Participant s that 
are not dispensed the  IMP are considered screen failures. 
Participant s will be informed that they are free to withdraw from the study at any time. Participant s 
should be questioned for the reason of premature withdrawal from the study, although they are not 
obliged to disclose it.  
Participant s discontinued from the study cannot re -enter the study.  
Participant s will be discontinued from the study for any of the following reasons: 
• Withdrawal of informed consent.  
• Any adverse effect or condition that would jeopardize continued safe study particip ation . 
• Discontinuation is considered to be in the best interest for the participant  or for other 
participant s participating in the study, as judged by the Investigator  or designee . Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
19
CCI
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 20 of 66 
Participant s may be  discontinued from the study for any of the following re asons based on the judgment 
of the Investigator:  
• No-show to appointments and unable to reschedule within the visit window.  
• The misuse or abuse of study related equipment.  
• Potential loss of the participant ’s data validity.  
• Unwilling or unable  to comply with  study procedures.  
4.7 LOST TO FOLLOW -UP 
For participant s lost to follow -up, three attempts to contact the participant  (including written 
correspondence and/or phone calls) will be made and documented in the source documents. The date 
of the last contact (e.g ., last visit, last phone call) will be recorded in the source document. When the PI 
(or designee) declares a parti cipant  is lost to follow -up, the lost to follow- up date will be recorded and 
will correspond to the date of the E nd of Study (EOS) of the participant . 
4.8 VIOLATION OF INCLUSION /EXCLUSION CRITERIA  
Participant s who, after signing the ICF, do not meet the inclusion and exclusion criteria will be 
considered screen failures. Re -screening for the study is not permitted.  
4.9 SESSION AND  RESPONSE WINDOWS  
4.9.1 V2 Session Window  
Participant s may attend V2  up to 28 calendar days post Screening Session (V1).  
4.9.2 V3 Session Window  
Participants may attend V 3 up to 3 calendar days post scheduled visit.  
4.9.3 All other v isit Window s 
Participant s may attend sessions up to three calendar  days  pre or post the scheduled visit.  
4.9.4 Daily Message  Response Window  
The survey response window will be open until the next  survey response  message is sent .  
 INVESTIGATIONAL MEDICINAL PRODUCT (IMP)  
5.1 CENTANAFADINE  SR (EB-1020)  
Centanafadine is an investigational drug that has inhibitory activity at norepinephrine (NE), dopamine 
(DA), and serotonin (5 -HT) reuptake transporters.1 It has the highest activity for inhibition for 
norepinephrine reuptak e (half- maximal inhibitory concentration [IC 50] 6 nM), but also inhibits dopamine 
(IC 50 38 nM) and serotonin (IC 50 83 nM) transporter reuptake.23  
Two phase 2 trials showed that the SR version of centanafadine was safe and well tolerated in adults 
with  attention deficit hyperactivity disorder (ADHD). The first study administered up to a TDD  of 500 mg Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
20
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 21 of 66 
(split into twice daily dosing) for two weeks .21 The second study compared TDDs of 400 mg, 600 mg, and 
800 mg in terms of  safety and efficacy for reducing ADHD symptoms.  Both studies concluded that 
centanafadine SR 400 mg TDD (200 mg BID) was effective and well tolerated and did not result in sleep 
disturbances, and there were no  signs of abuse or diversion.21 The most common adverse events 
reported were headache (20%, placebo = 9% ), decreased appetite (16%, placebo = 0%), and upper 
respiratory tract infection (16%, placebo = 11%).21 
5.1.1 Packaging and Labeling  
Trial medication will be provided to the investigators and the persons designated by the investigator(s) 
or institution(s) by the sponsor or designated agent. Trial medication will be labeled to clearly disclose 
the trial number, sponsor’s name and address, instructions for use, r oute of administration, and 
appropriate precautionary statements.  
5.2 DOSING REGIMEN  
Centanafadine SR will be administer ed orally at a 400 mg TDD (200 mg BID) approximately 4 to 6 hours 
apart for a total of seven weeks. Doses of centanafadine SR can be taken without regard to meals and 
should be taken at approximately the same time each day, with the first dose taken in the morning. The second dose should be taken 4 to 6 hours after the first dose.   If a subject forgets to take their second 
dose, they can take it up to 7 hours after their first  dose ; if they remember after 7 hours,  they should 
skip the dose and resume dosing the next day.  
5.2.1 Dosing Rationale  
The 400 mg dose of centanafadine SR will be evaluated in this study.  This dose was found to produce a significant blockade (>10%) of transporters for serotonin, dopamine, and norepinephrine as well as 
alleviating symptoms of inattention and hyperactivity/impulsivity in patients with ADHD, without 
inducing a high incidence of nausea and headache that occur with doses as high as 800 mg.
1  
5.2.2 Dose Adjustment Procedures  
The IMP dose may be considered for a one time dose decrease based on tolerability and/or adverse events. A one -time dose de crease to 200mg TDD (one pill in am and one pill in pm), based on the clinical 
judgement of the investigator. The subject would remain on the decreased dose (200mg TDD) for the 
remainder of trial participation. If tolerability / AE  does not resolve, post IMP dose -reduction, the 
subject should be considered for trial discontinuation, based on investigator judgement.  
5.3 STORAGE AND ACCOUNTABILITY  
5.3.1 Storage  
The IMP will be stored in a securely locked cabinet or enclosure. Access will be limited to investigators and their designees. Neither investigators nor any designees may provide IMP to any participant  not 
participating in this protocol.  
The IMP will be st ored at controlled room temperature conditions as per the clinical label on the IMP. 
The IMP  storage location will be monitored by TempAlert , temperatures will be recorded every 10 
minutes , with alerts triggered (via email, SMS, and phone call) when a temp erature falls out -of-
threshold (Severity 3), when a temperature is at risk of going out -of- range (Severity 2), and when a Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
21
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 22 of 66 
temperature has gone out- of-range (Severity 1). For detailed information about temperature 
monitoring, please refer to RRC’s SOP CLN040 – Facility Temperature Procedures with TempAlert.   
5.3.2 Accountability  
The investigator or designee will maintain an inventory record of IMP received, dispensed, administered, 
and returned.  
5.3.3 Destruction  
The IMP may only be destroyed by the trial site(s), if a pproved by the sponsor and if the IMP destruction 
meets all local regulations. The IMP will be destroyed by the clinical trial site following completion and 
verification of accountability of the IMP by the assigned trial monitor. The trial site(s) may utilize 
qualified third -party vendors for IMP destruction. A certificate of destruction should be filed within the 
IMP accountability.  
5.4 PRODUCT QUALITY COMPLAINTS  
A Product Quality Complaint (PQC) is any written, electronic, or oral communication provided by a healthcare professional, clinical trial participant , medical representative, regulatory agency, Partner, or 
other third party that alleges deficiencies related to the identity, quality, durability, reliability, safety, or 
performance of a Medical Device or Medicinal Product after it is released for distribution.  
Examples include, but are not limited to, communications involving:  
• Failure of a product to meet any of its specifications  
• Packaging defects (e.g., damaged, dirty, crushed, missing product or component, incorrect or 
missing labeling)  
• Product defects ( e.g., odor, chipped, broken, damaged, crushed, embossing illegible, under -
filled bottle, over -filled bottle, empty bottle, no safety seal)  
• Loss or theft  of product  
5.4.1 Eliciting and Reporting a PQC  
The investigator or designee must record all PQCs identified through any means from the receipt of the 
IMP from the sponsor or sponsor’s designee, through and including reconciliation and up to destruction, 
including participant  dosing. The investigator or designee must notify the sponsor (or sponsor’s 
designee) by e- mail within 24 hours of becoming aware of the PQC according to the procedure outlined 
below:  
Send PQC reporting information to Otsuka Pharmaceutical Development & Commercialization, Inc.  
(OPDC ) IMP PQC mailbox email: IMP -PQC@otsuka -us.com .  Also indicate whether or not the complaint 
sample is available for return.  
Identification of a PQC by the participant  should be reported to the site/investigator, who  should then 
follow the reporting mechanism above.  
5.4.2 Information Required for Reporting Purposes  
• Description of complaint  
• Reporter identification ( e.g., investigator, site, etc.)  
• Reporter contact information ( e.g., address, phone number, e -mail address)  
• Subject number  Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
22
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 23 of 66 
• Clinical site number  
• ID of material (product/compound name, lot/batch number, shipment number, expiry date)  
• Clinical protocol reference (number and/or trial name)  
• Dosage form/strength (if known)  
• Pictures of complaint sample (if available)  
• Availability of complaint sample for return  
5.4.3 Return Process  for Complaint Sample  
Indicate during the report of the PQC if the complaint sample is available for return.  
If complaint sample is available but not at the clinical site, please instruct participant  to bring the 
complaint sample to their next site visit.  
If complaint sample is available for return, the return instructions will be provided by the sponsor.  
It must  be documented in the site accountability record that the complaint sample has been forwarded 
to the sponsor for complaint investigation.  
5.4.4 Assessment and Evaluation  
Assessment and evaluation of PQCs will be handled by the sponsor.  
 STUDY PROCEDURES  AND ACTIV ITIES 
Personnel performing study assessments must have appropriate and documented training. An overview 
of all study assessments is shown in the Schedule of Events . Study personnel will adhere to standard 
operating procedures (SOPs) for all activities. Appropriate medical advice will be provided by qualified 
staff (licensed providers) to the participant  in case of any medical findings requiring health care.  
6.1 INFORMED CONS ENT AND GUIDANCE  
Prior to any study assessments being performed, the participant  will be asked to provide their written 
consent to participate in the study on an informed consent form (ICF). All assessments must start after the time of ICF signature by the  participant  for study participation.  
Designated staff, under the supervision of the Principal Investigator, will obtain informed consent from each participant. The person obtaining consent provides the participants with a printed document that 
explains the procedures and risks. Designated staff will answer any questions. A signed copy of the informed consent form will be given to each participant. Participants are informed that they may withdraw from participation in the study at any time without penalty.  
6.2 VIRTUAL SCREENING PROCEDURES   
To protect against unnecessary risk in the COVID -19 environment,  many aspects of screening  may  be 
conducted virtually. Potential participants will be sent  the IRB approved consent form via electronic 
signature . Consenting will take place via virtual meeting  where  information about  the study  will be 
explained to potential participants,  with  adequate time  allowed  for questions to be answered.  Once  the 
consent form is signed, the participant will be sent a secure link to complete screening questionnaires. Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
23
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 24 of 66 
These questionnaires will be reviewed by medical and research staff to determine eligibility  prior 
to scheduling the On -Site Visit.   
  
 
 
 
 
 
  
6.4 SAMPLINGS FOR PHARMACOKINETICS (PK) 
Blood s amples will be taken to determine concen trations of centanafadine and metabolites to assess 
compliance with dosing. The date and time of the sample collection and the date and time of last dose 
of IMP prior to sample collection will be recorded in the CRF. Concentrations of the IMP will be liste d in 
the bioanalytical report.  
6.5 SAFETY EVALUATIONS AND OTHER ASSESSMENTS  
Clinical safety evaluations will be performed to ensure that participants  meet the requirements of the 
study and to monitor participant  safety. An overview of all assessments is provided in the schedule of 
events . 
Urine will be collected, and blood will be drawn from each subject prior to treatment with 
centanafadine. Additional urine and blood samples may be collected for further evaluation of safety as 
warranted b y the investigator’s judgment. Reports from the laboratory will be assessed by the 
investigator or qualified designee for clinical significance.  
The results of the clinical chemistry, hematology and urine analysis safety panel will not routinely be given t o participant s to send or be sent to their physician to include in their medical record. However, if 
the participant ’s laboratory results are clinically relevant (including positive pregnancy tests), the 
research medical staff will send the participant  a copy of the laboratory results. Participant s who are 
accepted into the study but need medical follow- up due to minor abnormalities in laboratory results (at 
any session) will also receive a copy of the laboratory results.  
Additional urine and blood samples may be collected for further evaluation of safety as warranted by the investigator’s judgment. Reports from the laboratory will be assessed by the investigator or qualified designee for clinical significance.
 
  Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
24
CCI
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 25 of 66 
6.5.1 Clinical Chemistry  
Blood will be collected  for Clinical Chemistry tests at the screening visit (V1), V4 and the final study visit 
(V6).  
Clinical Chemistry  
Sodium   Chloride  
Potassium   Carbon dioxide  
Urea nitrogen (BUN)  Creatinine   
Glucose  Calcium  
Protein , total  Albumin   
Bilirubin , total  Alkaline phosphatase (AP)  
Aspartate aminotransferase (AST)  Alanine aminotransferase (ALT)  
Glycosylated Hemoglobin  (HbA1c ; at screening 
only)  Gamma -glutamyl transferase (GGT)  
Table 1 - Clinical Chemistry  
6.5.2 Hematology  
Blood will be collected for Hematology  tests at the screening visit  (V1), V4 and the final study visit (V6).  
Hematology  
Red blood cell (RBC) count   WBC count   
Hemoglobin   Differential white blood cell (WBC) count   
Hematocrit  Platelet count   
Mean corpuscular volume (MCV)  Mean corpuscular hemoglobin concentration 
(MCHC)  Mean corpuscular hemoglobin (MCH)  
Table 2 - Hematology  
6.5.3 Serum Pregnancy Test  
Blood will be collected for a serum pregnancy test at the screening visit (V1) for all participants with the 
potential to become pregnant . In case of any positive pregnancy test, the Investigator or designee will 
inform the participant about the risks associated with smoking during pregnancy.  
Serum Pregnancy Test  
Quantitative human chorionic gonadotropin (HCG) test  
Table 3 - Serum Pregnancy  
6.5.4 Urin alysis  
A urine sample will be collected for Urinalysis at the screening visit (V1) and the final study visit (V6).  
Urinalysis  
pH Glucose  
Red blood cell traces  Specific gravity  
Bilirubin  Nitrite  
Protein  WBC Esterase  
Table 4 - Urinalysis  
6.5.5 Urine Drug Screen  
A urine samples will be collected for a drug screen at the screening visit (V1) , V4 and V5 . Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
25
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 26 of 66 
Drug Screening  
Amphetamine  
Cocaine  
THC 
Methamphetamine  
Opiates  
Table 5 - Drug Screening  
6.5.6 Urine Pregnancy Test  
A urine sample will be collected for a pregnancy test at all study visits (excluding screening). All positive 
urine pregnancy test results will be confirmed by a serum test.  Participants  with a positive serum 
pregnancy test result during the trial must discontinue treatment and be withdrawn from the trial. Th e 
Investigator or designee will also inform the participant about the risks associated with smoking during 
pregnancy.  For additional information please refer to  Section 9.8 Pregnancy after Enrollment .  
6.5.7 Electro cardiogram (ECG)  
ECG recording will be performed and interpreted at RRC by qualified personnel. A standard 12 -lead ECG 
will be recorded after the participant  has rested for at least 5 minutes in a supine position.  
Data and evaluations from ECGs will be reported on the individual participants’ CRFs  and transferred to 
Otsuka via the EDC database. Original ECG tracings will remain at the site (RRC) within the source 
documentation . 
6.5.8 Vital Signs  
Vital signs (systolic and diastolic blood pressure, pulse rate, temperature and respiratory rate), will be 
measured in sitting position after the participant  has rested for at least 5 minutes.  After two minutes of 
standing, a second blood pressure reading (systolic and diastolic) and pulse rate will be obtained at the 
screening visit (V1).  
6.5.9 Physical Examination  
A complete physical examination, including auscultation and palpation will be performed. A complete 
physical examination will include review of general appearance, hair and skin, head, eyes, ears, nose and 
throat, neck, chest, abdomen, dentition, cardiovascular, musculoskeletal and neurological systems. The physical examination is to be conducted by a designated fully trained representative.  
Appropriate medical recommendations will be provided to the participant  if any medical findings 
requiring health care are identified.  
6.5.10  Expired Air CO Breath Test  
Carbon Monoxide (CO) in participant ’s exhaled breath (expressed as ppm)  will be measured using a 
Vitalograph Breath CO Monitor. Participant s must have an expired air CO reading at V1 of at least 10 
ppm for inclusion into this study. This test will be repeated at each of the visits . 
6.5.11  Medical History and Concomitant Disease  
Relev ant medical history and concomitant disease will be documented at the screening visit (V1). 
Medical history is defined as any condition that started and ended prior to screening. A concomitant Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
26
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 27 of 66 
disease is defined as any condition that started prior to screening and is still ongoing at V2 (this may also 
include findings detected during the screening visit (V1)).  
6.5.12  Prior and Concomitant Medication  
All medication taken 30 days prior to the screening visit (V1) and during the study will be documented. 
Medications which are stopped before V2  will be considered as prior medication s. Medications which 
are started prior to the screening visit (V1) and which are still being taken by the participant  during the 
study, as well as medications that are initiated after the screening visit (V1) will be considered as 
concomitant medications. This applies to both prescription and over -the-counter products (e.g., 
vitamins). 
Records of prior and concomitant medications taken include the drug name (preferably both generic and trade name), route of administration, dose/unit, frequency of use, indication, the start and, if 
applicable, the stop date. Any therapy changes (including changes of regimen) during the study will be 
documented.  
6.5.13  Body Height and Body Weight  
Body weight will be measured at each visit. Height and weight will be measured at screening, and body 
mass index (BMI) will be calculated.  
6.5.14  Demographics  
Sex assign ed at birth, sex currently identified with , date of birth, race and ethnicity will be recorded for 
each participant  according to the Schedule of Events . 
6.5.15  AE/SAE Reportin g 
AEs/SAEs will be assessed using questionnaires and interviews at the indicated time points and spontaneous reporting from the time of ICF signature until the EOS for the participant  the Schedule of 
Events . 
6.5.16  Questionnaires  
The questionnaires will be administered to the participant s using paper questionnaires and/or an 
electronic data collection system. The questionnaires will be asked according to  the Schedule of Events . 
 C-SSRS – The Columbia -Suicide Severity Rating Scale  
The C -SSRS is an assessment tool that evaluates suicidal ideation and behavior.24 The “Screening” 
Version will be used for the first administration (at the screening visit). This version will include an assess ment of suicidal ideations over the past 12 -months and an assessment of suicidal behaviors over 
the past 24 months. Subsequent visits will utilize the “Since Last Visit ” Version.  
 Modified Cigarette Evaluation Questionnaire  Extended (mCEQE)  
The Cigarette Evaluation Questionnaire was initially developed in the PI's laboratory and used in numerous studies to assess the effects of pharmacological treatments on the rewarding effects of cigarette smoking. The mCEQE will be utilized to assess the degree to which participant s experience the 
reinforcing of smoking, providing five subscale scores: smoking satisfaction (satisfying, tastes good, 
enjoy smoking), psychological rewards (calms down, more awake, less irritable, helps concentrat e, 
reduces hunger), aversion (dizziness, nauseated), enjoyment of respiratory tract sensations (single -item 
assessment), craving reduction (single -item assessment). Participant s will be asked to assess the 12 Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
27
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 28 of 66 
items of the questionnaire on a 7 -point scale, ranging from “not at all” to “extremely”. These 12 items 
will be asked for the “first cigarette smoked”, “cigarette immediately after a meal”, and “all other 
cigarettes.”  
 Modified Shiffman -Jarvik  Withdrawal Scale  
The Modified Shiffman -Jarvik Withdrawal Scale  is used to measure withdrawal symptoms and a 
participant ’s desire to smoke. This scale consists of five subscales: craving, psychological symptoms, 
physical symptoms, sedation, and appetite.25  
 Reasons to Smoke  
The Reasons to Smoke questionnaire is used to determine the most important reasons to smoke for 
each participant . 
 The Fagerström Test for Nicotine Dependence  (FTND)  
The Fagerström Test for Nicotine Dependence is a six -item questionnaire developed by Karl -Olov 
Fagerström and is used to determine someone’s level of nicotine dependence. The scores obtained on 
the test allow the classification of nicotine dependence in three different levels: mild (0 -3 points), 
moderate (4 -6 points), and severe (7 - 10 points).   
 Smoking History Questionnaire  
The Smoking History is a questionnaire designed to help assess the participant ’s current and past 
smoking habits. This questionnaire  will be administered at screening (V1) and  will include questions 
about the  number of years participant s have smoked combustible cigarettes (CC) , the number of CC s per 
day smoked over the last 12 months, brand of CC s, use of other tobacco products and use of nicotine 
replacement therapy or other smoking cessation treatments. This questionnaire will also be used  to 
check eligibility criteria.  
 Other Nicotine Use  Questionnaire  
The Other Nicotine Use questionnaire will be used to capture information abo ut the use of nicotine 
containing products (other than combustible cigarettes). This questionnaire will be given at V2 and all subsequent visits , including safety follow -up.  
 Minneso ta Nicotine Withdrawal Scale  (MNWS)  
The MNWS  is used to assess nicotine wi thdrawal symptoms including craving and mood effects . 
Participants will be asked to assess eight symptoms  on a 5- point scale ranging from 0 to 4, where 0  = 
none, 1 = slight, 2 = mild , 3 = moderate, 4 = severe. 
 Study Drug Compliance  
Participant s will be queried via electronic  messages whether they have been compliant with taking the 
study drug. These messages will  commenc e after the second visit (V2) and continue through the End of 
Study . 
 Smoking Status  
Electronic  messages will be sent to participant s starting after the second visit (V2), through the End of 
Study, to ascertain the participant s smoking status . Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
28
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 29 of 66 
6.6 VISIT PROCEDURES  
6.6.1 Screening (V1)  
Eligibility of participants to participate in this study will be assessed at the screening visit (V1). The ICF 
will be signed, dated and timed prior to any other screening procedures.  At the end of  this visit, 
participants will be given instructions on the use of the messaging and questionnaire system that will be used daily to collect information about smoking status (starting the next day) and IMP compliance  (after 
V2). 
The sequence of the following questionnaires and assessments will be at the discretion of the Investigator (or designee) after signature of the ICF.  Whenever possible, blood draws should be 
performed  after  all other assessments are complete.  
 Questionnaires  
• Smoking History  
• Registration Form  
• Medical History (with Review of Systems)  
 Assessments  
• Review of Prior and Concomitant Medication 
• Review of Concomitant Disease and Medical History  
• Expired air CO breath test  
• Alcohol breath test  
• Urine collection for urinalysis  and drug screen  
• Blood collection for safety laboratory testing (including pregnancy test for all females ) and 
for future biospecimen research (for those participants who consented to this optional 
collection)  
• Vital signs (systolic and diastolic blood pressure, pulse rate, and respiratory rate), will be measured in sitting position after the participant has re sted for at least 5 minutes. After 
two minutes of standing, a second blood pressure reading (systolic and diastolic) and pulse 
rate will be obtained. 
• Height and weight / BMI  
• Temperature  
• Electrocardiogram (ECG)  -- A standard 12 -lead ECG will be recorded aft er the participant 
has rested for at least 5 minutes in a supine position.  
• Columbia- Suicide Severity Rating Scale (C -SSRS)  
• Physical examination  
6.6.2 Baseline (V2)  – Day -1 
Visit 2 will occur within 28 days of the screening visit. Participants will come to the Center to complete 
questionnaires, assessment s, and for dispensing of IMP. Participants will begin the study drug regimen 
the day after V2  (Day 1) . Date and time of first dose will be collected  via electronic  message. 
The sequence of the following ques tionnaires and assessments will be at the discretion of the 
Investigator (or designee ).  Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
29
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 30 of 66 
 Questionnaires  
• Reasons to Smoke  
• Other Nicotine Use Q uestionnaire  
• Modified Cigarette Evaluation Questionnaire Extended ( mCEQE) 
• Minnesota Withdrawal Questionnaire  
• Modified Shiffman -Jarvik Withdrawal Scale  
• Fagerström Test for Nicotine Dependence  
 Assessments  
• Review of Concomitant Medication  
• Review of Concomitant Disease  
• Expired air CO breath test  
• Urine collection for pregnancy (all participants with th e potential to become pregnant) 
• Vital signs (systolic and diastolic blood pressure, pulse rate, and respiratory rate), will be 
measured in sitting position after the participant has rested for at least 5 minutes . 
• Weight  
• Temperature  
• Columbia- Suicide Severit y Rating Scale (C -SSRS)  
• Review of adverse events (as needed)  
• Physical examination (as needed)  
6.6.3 Day before Quit Day (V3) – 1 week on IMP  
Six days ( + 3 days) after starting the study drug (one day prior to quit date), participants will return to 
the Center to complete questionnaires  and assessments . Participants will also  be asked to  return  unused 
IMP and will be dispens ed enough IMP to last until the next scheduled visit .  
The sequence of the following questionnaires and assessments will be at the discretion of the 
Investigator (or designee).  
 Questionnaires  
• Other Nicotine Use Questionnaire  
• Modified Shiffman -Jarvik Withdrawal Scale  
• Modified Cigarette Evaluation  Questionnaire Extended (mCEQE) 
• Minnesota Withdrawal Questionnaire  
 Assessments  
• Review of Concomitant Medication  
• Review of Concomitant Disease  
• Expired air CO breath test  
• Urine collection for pregnancy (all participants with the potential to become pregnant ) 
• Vital signs ( systolic and diastolic blood pressure, pulse rate, and respiratory rate), will be 
measured in sitting position after the participant has rested for at least 5 minutes.  
• Weight  
• Temperature  
• Columbia- Suicide Severity Rating Scale (C-SSRS)  Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
30
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 31 of 66 
• Review of adverse events (as needed)  
• Physical examination (as needed)  
6.6.4 Visit 4 (V4)  – 3 weeks on IMP  
Three weeks (± 3 days) after starting the study drug , participants will return to the Center for V4 to 
complete questionnaires and assessments. Pa rticipants will also be asked to return unused IMP and will 
be dispensed enough IMP to last until the next scheduled visit.   
The sequence of the following questionnaires and assessments will be at the discretion of the 
Investigator (or designee).  
 Questio nnaires  
• Other Nicotine Use Questionnaire  
• Modified Shiffman -Jarvik Withdrawal Scale  
• Modified Cigarette Evaluation Questionnaire Extended (mCEQE)  
• Minnesota Withdrawal Questionnaire  
 Assessments  
• Review of Concomitant Medication  
• Review of Concomitant Disease  
• Expired air CO breath test  
• Urine collection for drug screen  and pregnancy (all participants with the potential to become 
pregnant ) 
• Blood collection for safety laboratory testing , pharmacokinetics , and  future biospecimen 
research (for those participants who consented to this optional collection)  
• Vital signs ( systolic and diastolic blood pressure, pulse rate, and respiratory rate), will be 
measured in sitting position after the participant has rested for at least 5 minutes.  
• Weight  
• Temperature  
• Columbi a-Suicide Severity Rating Scale (C -SSRS)  
• Review of adverse events (as needed)  
• Physical examination (as needed)  
6.6.5 Visit 5 (V5)  – 5 weeks on IMP  
Five weeks ( ± 3 days) after starting the study drug, participants will return to the Center for V5 to 
complete questionnaires and assessments. Participants will also be asked to return unused IMP and will 
be dispensed enough IMP to last until the next scheduled visit.  
The sequence of the following questionna ires and assessments will be at the discretion of the 
Investigator (or designee).  
 Questionnaires  
• Other Nicotine Use Questionnaire  
• Modified Shiffman -Jarvik Withdrawal Scale  
• Modified Cigarette Evaluation Questionnaire Extended (mCEQE)  
• Minnesota Withdrawal Questionnaire  Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
31
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 32 of 66 
 Assessments  
• Review of Concomitant Medication  
• Review of Concomitant Disease  
• Expired air CO breath test  
• Urine collection for drug screen and pregnancy (all participants with the potential to become 
pregnant ) 
• Vital signs ( systolic and diastolic blood pressure, pulse rate, and respiratory rate), will be 
measured in sitting position after the participant has rested for at least 5 minutes.  
• Weight  
• Temperature  
• Columbia- Suicide Severity Rating Scale (C -SSRS)  
• Review of adverse events (as needed)  
• Physical examination (as needed)  
6.6.6 Final Study Visit (V6)  – 7 weeks on IMP  
Seven  weeks (± 3 days) after starting the study drug, participants will return to the Center for V6 to 
complete questionnaires and assessments. Participants will also be asked to return all unused IMP.  
The sequence of the following questionnaires and assessments will be at the discretion of the 
Investigator (or designee).  
 Questionnaires  
• Other Nicotine Use Questionnaire  
• Modified Shiffman -Jarvik Withdrawal Scale  
• Modified Cigarette Evaluation Questionnaire Extended (mCEQE)  
• Minnesota Withdrawal Questionnaire  
• Fagerström Test for Nicotine Dependence  
 Assessments  
• Review of Concomitant Medication  
• Review of Concomitant Disease  
• Expired air CO breath test  
• Alcohol breath test  
• Urine collection for urinalysis  and pregnancy (all participants with the potential to become 
pregnant ) 
• Blood collection for safety laboratory testing, pharmacokinetics, and future biospecimen 
research (for those participants who consented to this optional collection)  
• Vital signs ( systolic and diastolic blood pressure, pulse rate, and respiratory rate), will be 
measured in sitting position after the participant has rested for at least 5 minutes.  
• Weight  
• Temperature  
• Electrocardiogram (ECG)  -- A standard 12 -lead ECG will be recorded after the participant has 
rested for at least 5 minutes in a supine position.  
• Columbia- Suicide Severity Rating Scale (C -SSRS)  
• Review of adverse events (as needed)  Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
32
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 33 of 66 
• Physical examination (as needed)  
6.6.7 Telephone Contact  
Participants will be contacted via phone on Day 1 (first day of IMP) and on weeks that they are not 
scheduled to visit the Center (Wk 2, Wk 4, and Wk 6 ) to ask how they are doing and answer any 
questions the participant may have.  
6.6.8 Safety Follow -Up 
Seven to  10 days  after V6 , participants will be contacted via phone  for a safety follow -up.  
 Questionnaires  
• Other Nicotine Use Questionnaire  
• Modified Cigarette Evaluation Questionnaire Extended (mCEQE)  
• Minnesota Withdrawal Questionnaire  
 Assessments  
• Review of Concomitant Medication  
• Review of Concomitant Disease  
• Review of adverse events  
6.7 DAILY MESSAGING  
Rose Research Center will utilize eResearch, an IRB approved proprietary mobile electronic application 
for clinical research studies available in both the iOS and Android app stores. For the purposes of this 
protocol, the Survey’s feature will be utilized to push the daily messages to enrolled participants.  
Daily text reminders and/or push notifications may be paired with these daily messages in order to  
remind participants about the request to complete these assessments.  
6.7.1 Daily Message (after screening, prior to V2)  
Participants will receive a push notification  with a prompt  to a daily survey to access the following:  
• Have you smoked any combustible cigarettes today?  
o If yes, how many cigarettes did you smoke?  
6.7.2 Daily Message (Visit 2  through V6 ) 
Participants will receive a push notification  with a prompt  to a daily survey to assess the following:  
• Have you smoked any combustible cigarettes to day?  
o If yes, how many cigarettes did you smoke?  
• Did you take your 1st dose of study drug today ? 
• Did you take your 2nd dose of study drug today ? 
o If yes, did you take the 2nd dose 4 to 6 hours after the 1st dose?  Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
33
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 34 of 66 
6.8 SCHEDULE OF EVENTS  
  
Table 6 - Schedule of Event  Study Week SCRWk 0
BaselineWk 1
(+ 3 days)Wk 2 - Wk 3
(± 3 days)Wk 4 - Wk 5 
(± 3 days)Wk 6 - Wk 7 
(± 3 days)Wk 8
(+ 2 days)
Visit V2 V3 V4 V5 V6
IMP Timeline Day -1 Day 1 IMP Wk 1 IMP Wk 3 IMP Wk 5 IMP Wk 7 IMP
Informed Consent x
Inclusion/Exclusion Crite ria x  x 
Enrollment  x 
Visit Pre paration x  x  x  x  x  x 
Visit Re minde r Calls x  x  x  x  x  x 
Telephone Contact -(Day 1, Wk 2, Wk 4, Wk 6, and 7 day F/U)  x  x  x  x  x 
Reasons to Smoke  x 
Smoking History x
Other Ni coti ne Use  x  x  x  x  x  x 
Registration Form x
Me dical History with Re vie w of Syste ms x
Modified Cigarette Evaluation Questionnaire Extended (mCEQE)  x  x  x  x  x  x 
The Fagerström Test for Ni coti ne Dependence (FTND)  x  x 
Modifie d Shiffman-Jarvik Withdrawal Scale  x  x  x  x  x 
Minnesota Withdrawal Questionnaire  x  x  x  x  x  x 
The Columbia-Suicide Severity Rating Scale (C-SSRS) x x x x x x
 Smoking Status  (via daily messages ) x  x  x  x  x  x  x 
Medi cati on Adherence (vi a dai l y messages)  x  x  x  x  x  x 
Clinical Che mistry x  x  x 
CBC w/Diff & Platelet Count x  x  x 
Serum Pregnancy Test* x
HbA1c x
PK Blood Draws  x  x 
Urinalysis Safety Panel x  x 
Drug Screen x  x  x 
Pregnancy  x  x  x  x  x 
Prior and Concomitant Medication Assessment and Medical Review x  x  x  x  x  x  x 
Concomi tant Di sease Assessment and Medi cal  Revi ew x  x  x  x  x  x 
CO Breath Test x  x  x  x  x  x 
ECG x  x 
Blood Pressure - Sitting and Standing Positions x  x  x  x  x  x 
Heart rate x  x  x  x  x  x 
Temperature x  x  x  x  x  x 
Respiratory rate x  x  x  x  x  x 
Wei ght x  x  x  x  x  x 
Physical Examination (as needed) x  x  x  x  x  x 
Al cohol  Breath Test x
AE Intervi ew and Assessment  x  x  x  x  x  x 
Collect Used/Unused IP  x  x  x  x 
Di spense IP  x  x  x  x 
IMP Dosing  x  x  x  x  x 
* Serum pregnancy test will be done if urine pregnancy test is positiveOther Assessments
ProceduresSafety 
Follow-up
Questionnaires
Blood Samples
Urine SamplesV1Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
34
CCI
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 35 of 66 
 RISK / BENEFIT  INFORMATION  
7.1 POTENTIAL BENEFITS  
The participants will be encouraged to quit smoking, which would significantly reduce their risk of 
smoking -related diseases.  
7.2 IMPORTANCE OF KNOWLEDGE TO BE GAINED  
The proposed study could lead to the development of a new approach to smoking cessation  that would 
have a major positive impact on public health worldwide  along with associated comorbid conditions . 
7.3 POTENTIAL RISKS 
7.3.1 Centanafadine SR  
The most common adverse  effect s reported in other studies  of centanafidine SR include: decreased 
appetite, headache, nausea, dry mouth diarrhea, fatigue, insomnia, rash  (refer to  Section 9.5  for 
additional information ), dizziness , heart rate increase when standing from a sitting position, irritability, 
abdominal pain, change in sense of taste.1 
7.3.2 Tobacco Withdrawal  
To the extent that nicotine or oth er tobacco smoke constituent intake is reduced or eliminated, 
participants may experience tobacco withdrawal symptoms, including craving, difficulty concentrating, mood disturbance and increased appetite/weight gain.  
7.3.3 Blood Draw  
The risks associated with v enipuncture are minimal and include momentary discomfort and/or  bruising. 
Infection, excess bleeding, clotting, and fainting  are also possible, although unlikely.  
7.4 CONCOMITANT MEDICATIONS  
All medication taken 30 days  prior to the screening visit (V1) and during the study will be documented 
using a source document. Medications which are stopped before V 2 will be considered as prior 
medication. Medication which was started prior to V1 and which is still being taken by t he subject during 
the study as well as medication that is initiated after V2 will be considered as a concomitant medication. 
This applies to both prescription and over -the-counter products (e.g., vitamins).  
Records of prior and concomitant medications take n include the drug name (preferably both generic 
and trade name), route of administration, dose/unit, frequency of use, indication, the start and if applicable, the stop date. Any therapy changes (including changes of regimen) during the study have to be d ocumented . Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
35
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 36 of 66 
7.5 PROTECTION AGAINST RISKS 
Participants will be screened medically and monitored throughout the study.  Study participants will 
receive detailed instructions on the use of the IMP  distributed to them, in order to minimize the 
possibility of misuse.  Participant s will be instructed to keep the study drug away from children and pets.  
Participants will be instructed to report any side effects to study staff, who will communicate these 
reports to the medical staff. The most appropriate course of action w ill be determined, which may 
include options for termination of exposure to the study drug. Participants will, however, be reminded 
that they have the option to withdraw from the study at any time. Participant s will also be given a 24 -
hour emergency contac t number in the event that side effects or adverse events occur between 
sessions. 
7.5.1 Blood Pressure Monitoring  
Cigarette smoking affects blood pressure in many ways, including stimulation of the sympathetic 
nervous system, but also through acute inflammation, impairment of endothelial function, and increased arterial stiffness.
26 In 2017, the American College of Cardiology set forth stricter 
recommendations for treatment of elevated blood pressure, with the goal of commencing treatment 
(lifestyle changes and/or medication) starting at 130/80, vice 140/90.27 The definition of systemic 
arterial hypertension (commonly known as hypertension) did not change with these new 
recommendations from the American College of Cardiology. Hypertension is characterized by persisten tly high blood pressure in the systemic arteries, with an “Office BP” of > 140 mmHg systolic and 
> 90 mmHg diastolic.28 
This study will use a blood pressure of 150/95 as a cutoff for eligibility, recognizing that most 
participants have recently smoked just prior to arriving for the screening process, and that many of 
them will have additional sympathetic activation through the ingestion of caffeinated beverages.   
Any participant who presents with blood pressure > 140 mmHg systolic and/o r > 90 mmHg diastolic will 
be counselled, with recommendations to monitor blood pressure at home and follow up with their primary care provider. Participants who enroll in the study will have blood pressure checks at every office visit. 
 QUALITY CONTROL AND  QUALITY ASSURANCE  
8.1 MONITORING  ACTIVITIES  
An independent Monitor will be contracted by RRC and will be responsible for the monitoring activities. 
Monitoring will be performed as per the agreed monitoring plan . A minimum of the following types of 
monitoring visits will occur for this study.  
8.1.1 Site Initiation Visit (SIV)  
A Site Initiation Visit will be conducted by the Monitor prior to site activation to confirm preparedness 
for protocol execution, satisfactory site facilities, clarify the applicable regulations and requirements of 
the protocol, carefully review the process of implementing the protocol at the site and conduct any 
necessary training prior to activating the site for enrollment.  Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
36
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 37 of 66 
8.1.2 Interim Monitoring Visits (IMVs)  
Interim Monitoring Visits will be conducted to confirm participants’ rights are being protected; the study 
is being conducted according to the protocol and applicable regulations; and to confirm accurate 
reporting of participant safety data and study endpoints.  
8.1.3 Close -Out Visit  (COV )  
A Close -Out Visit will be conducted to ensure that all study data and other study documentation is 
complete and accurate and that all study records have been reconciled.  
8.2 TRAINING OF STAFF 
The Investigator or designee will ensure that appropriate training relevant to the study is provided to all 
staff involved in the study, and that any new information relevant to the performance of this study is forwarded in a timely manner to the staff.  
8.3 AUDITS AND INSPECTIONS  
Good Clinical Practice regulations require independent inspections of clinical program activities. Such 
inspections may be performed at any time before, during, and after the study.  
Authorized representatives of the Sponsor, regulatory agencies and/or an IRB may perform audits o r 
inspections, including source data verification. The purpose of an audit or inspection is to systematically and independently examine all study -related activities and documents to determine whether these 
activities were conducted,  and data were recorded,  analyzed and accurately reported , according to the 
protocol, ICH/GCP guidelines and any applicable regulatory requirements. The Investigator or designee will contact the Sponsor immediately if contacted by a regulatory agency about an inspection at their site.  
The Investigator and study staff are responsible for maintaining a comprehensive and accurate filing system of all study -related documentation that will be suitable for inspection at any time by the 
Sponsor, its authorized representative , and other  regulatory agencies.  
 ADVERSE EVENTS  
9.1 DEFINITIONS  
9.1.1 Adverse Event  (AE) 
An AE is defined as any untoward medical occurrence in a patient or clinical trial participant  
administered a medicinal product and which does not necessarily have a causal relationship wit h this 
treatment. The AEs would not include information recorded as medical history at screening for 
preplanned procedures for which the underlying condition was known and no worsening occurred. An adverse reaction is any untoward and unintended response t o an IMP -related to any dose administered.  
A suspected adverse reaction is any AE for which there is a reasonable possibility that the IMP caused the AE. For the purpose of Investigational New Drug (IND) safety reporting, “reasonable possibility” Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
37
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 38 of 66 
means the re is evidence to suggest a causal relationship between the IMP and the AE. Suspected 
adverse reaction implies a lesser degree of certainty about causality.  
Any increase in the severity and/or  the frequency of a concomitant disease is considered an AE.  
9.1.2 Serious Adverse Event  (SAE)  
A Serious Adverse Event is any adverse event that results in any of the following outcomes : 
• Death  
• Life-threatening; ie, the participant  was, in the opinion of the investigator, at immediate risk 
of death from the event as it occurred. It does not include an event that, had it occurred in a 
more severe form, might have caused death.  
• Persistent or significant incapacity/disability or substa ntial disruption of the ability to conduct 
normal life functions.  
• Requires in -patient hospitalization or prolongs hospitalization.  
o Hospitalization itself should not be reported as an SAE; whenever possible the reason for the hospitalization should be reported.  
o Hospitalizations or prolonged hospitalizations for social admissions (ie, those required 
for reasons of convenience or other non -medical need) are not considered SAEs.  
• Congenital anomaly/birth defect.  
• Other medically significant events that, based upon appropriate medical judgment, may 
jeopardize the participant  and may require medical or surgical intervention to prevent one of 
the outcomes listed above; eg, allergic bronchospasm requiring intensive tre atment in an 
emergency room or home, blood dyscrasias or convulsions that do not result in hospitalization, or the development of drug dependency or drug abuse.  
9.1.3 Nonserious Adverse Event  
Adverse events are all AEs that do not meet the criteria for a "seriou s" AE.  
9.1.4 Immediately Reportable Event  (IRE)  
The following events will be reported immediately to the Sponsor.  
• Any SAE.  
• Any AE of special interest (AESI) . 
• Any AE related to occupational exposure.  
• Potential serious hepatotoxicity . 
• Confirmed pregnancy.  
9.1.5 Psychiat ric Adverse Events  
The investigator (or designee)  will review participant responses to the C -SSRS.  The C-SSRS w ill be used to 
screen for suicidal ideation within the last 12 months and suicidal behavior within the last 24 months from screening. Potential participants who score > 0 on the screening C -SSRS for suicidal ideations  
(answer “Yes” to questions 1 -5 in the SUICIDAL IDEATION  section) or a score >0 for Suicidal Behavior 
(answer “Yes” to any questions in the SUICIDAL BEHAVIOR  section) at screening (Visit 1) or at Baseline 
(Visit 2) will be excluded from study participation, and, at the discretion of the study physician/physician assistant, referred to appropriate psychiatric treatment. Th e C-SSRS will be administered by traine d 
clinical research staff at every visit, including the screening visit (V1 through V 6). The “Screening” 
version will be administered at V1, and the “Since Last Visit” version will be administered at V2 through Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
38
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 39 of 66 
V6, inclusive. Any changes in the scoring wil l be evaluated by licensed medical professionals, with 
recommendations for referral to appropriate medical care provided to the participant when required, at 
the discretion of the study physician/physician assistant.  
9.1.6 Changes in Clinical Laboratory Test Val ues 
It is the investigator’s (or designee’s) responsibility to review the results of all laboratory tests as they become available. This review will be documented by the investigator’s dated signature on the laboratory report. For each abnormal laboratory test result, the investigator needs to ascertain if this is an abnormal (ie, clinically significant) change from baseline for that individual participant . This 
determination, however, does not necessarily need to be made the first time an abnormal value is  
observed. The investigator may repeat the laboratory test or request additional tests to verify the results of the original laboratory tests. If this laboratory value is considered medically relevant by the investigator ( participant  is symptomatic, requiring corrective treatment or further evaluation), or if the 
laboratory value leads to discontinuation, and/or fulfills a seriousness criterion, this is considered an AE.  
9.2 COLLECTION OF SAFETY EVENTS FROM PARTICIPANT S 
The investigator will periodically assess participants  for the occurrence of AEs. To avoid bias in eliciting 
AEs, participants  should be asked the non -leading question: “How have you felt since your last visit?”  All 
AEs (serious and nonserious) reported b y the participant  must be recorded on the source documents 
and eCRF. Serious AE collection is to begin after a participant  has signed the eICF.  
Use medical terminology in AE reporting. Adverse events should be reported as a single unifying 
diagnosis whene ver possible or, in the absence of a unifying diagnosis, as individual signs or symptoms. 
Exacerbation or disease progression should be reported as an AE only if there are unusual or severe 
clinical features that were not present, or experienced earlier, o r not expected based on the course of 
the condition.  
Information recorded when collecting AE s will include: thorough  description of the AE, seriousness 
assessment, start and stop dates  (if known) , circumstances leading up to the event, clinical elements 
such as clinical course, specific vital signs and test results that may explain the pathophysiology of the 
event, as well as alternative explanations to its occurrence, the action taken with the investigation product/procedures  due to the AE, the participant `s disposition in the study after the occurrence of the 
AE and the final outcome of the AE  (if known) . 
Any exacerbation/worsening or increased frequency of an AE or pre -existing condition shall be 
evaluated and recorded.  
9.2.1 Period of Collection  
All existing health conditions identified during the Screening Period will be recorded as concomitant disease and the participant ’s eligibility will be reviewed. Any AEs which occur during the screening 
session will be captured by the study site staff and assessed by the Investigator or designee in order to establish relationship or relatedness in respect to study procedures.  
Any new, clinically relevant, abnormal finding detected during the study or worsening of a pre -existing 
condition/concomitant disease will be docum ented as an AE or  an SAE.  Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
39
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 40 of 66 
All ongoing AEs at the E nd of Study participation will be followed -up by the Investigator or designee until 
they have improved, resolved, stabilized (i.e., no worsening of condition), or until an acceptable 
explanation has been found. The Investigator or designee will refer the particip ant to their Primary Care 
Provider for follow up of those AE when appropriate.  
9.3 ASSESSMENT OF ADVERSE EVENTS  
9.3.1 Severity  of Adverse Events  
For each AE /SAE , the intensity will be graded on a 3 -point intensity scale:  
• Mild:  The AE is easily tolerated and does no t interfere with daily activity.  
• Moderate: The AE interferes with daily activity, but the participant  is still able to function.  
• Severe: The AE is incapacitating and requires medical intervention.  
9.3.2 IMP Ca usality  
In general, all AEs and SAEs will be assessed  by the Investigator or designee as either ‘related’ or ‘not  
related’ .  
• Not related: The temporal relationship of the clinical event to study procedures  and/or the 
study medication  makes a causal relationship unlikely, or, concomitant medication, 
therapeut ic interventions, or underlying conditions provide a sufficient explanation for the 
observed event.  
• Related: The temporal relationship of the clinical event to study procedures  and/or the study 
medication  makes a causal relationship possible, and concomitant medication, therapeutic 
interventions, or underlying conditions do not provide a sufficient explanation for the 
observed event.  
9.4 IMMED IATELY REPORTABLE EVENTS  
The investigator must immediately report after either the investigator or site personnel become aware 
of any SAE, AE related to occupational exposure, AESI, potential serious hepatotoxicity, or confirmed pregnancy , by telephone, fax, or e- mail to the spons or using the contact information on the cover page 
of this protocol. An IRE form must be completed and sent by e -mail, fax, or overnight courier to the 
sponsor (Please note that the IRE form is NOT the AE eCRF).  
Subjects experiencing SAEs should be followe d clinically until their health has returned to baseline 
status, or until all parameters have returned to normal or have otherwise been explained. It is expected that the investigator will provide or arrange appropriate supportive care for the subject and will provide prompt updates on the subject’s status to the sponsor.  
9.5 ADVERSE EVENTS OF SPECIAL INTEREST  Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
40
CCI
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 41 of 66 
9.6 ABUSE POTENTIAL MONITORING PLAN 
A key objective of the Abuse Potential Monitoring Process (APMP) is to monitor for instances of abuse 
or diversion of the trial medication and other psychoactive substances. In addition to monitoring for 
irregularities in medication handling, AEs that may be suggestive of a developing abuse issue will also receive special attention. As part of the APMP, medication handling irregularities (MHIs) must be reported, and AEs related to abuse potential and AEs involving MHIs must be repo rted as Events Subject 
to Additional Monitoring (ESAMs) with detailed narratives.  
Investigators and site staff at each trial site will be trained on reporting potentially abuse related AEs (eg, recording a description of the event in the participant ’s own  words in the source documents as well 
as the eCRF, in addition to the clinical term, and to be aware that a participant ’s report may encompass 
more than one event and that these should be recorded separately). The investigators will be provided with examples of potentially abuse -related AEs, and trained on how to handle such events (eg, 
additional monitoring). While the investigators will be provided with examples of AE terms as a guide 
during trial conduct, the analysis of potentially abuse -related AEs wi ll be based on a search of all Medical 
Dictionary for Regulatory Activities (MedDRA) preferred terms, all verbatim terms, and any open text 
fields within the AE data to identify text strings suggestive of abuse potential, in line with the 2017 FDA guidance  (Assessment of Abuse Potential of Drugs).
29 Refer to the separate APMP documentation for 
complete details on MHIs and ESAMs, including documenting and reporting procedures, examples of potentially abuse related AE terms that meet the criteria for ESAM reporting, and guidance for the training of investigators and trial site staff.  
9.7 POTENTIAL SERIOUS HEPATOTOXICITY  
For a participant  who experiences  an elevation in aspartate aminotransferase (AST) or alanine 
aminotransferase (ALT) that is 3 times the upper limit of normal (ULN), a total bilirubin level should also be evaluated. If the total bilirubin is  2 times the ULN, complete an IRE form with all values listed and also 
report as an AE on the eCRF.  
9.8 PREGNANCY  AFTER ENROLLMENT  
During the trial, all FOCBP should be instructed to contact the investigator immediately if they suspect they might be pregnant (eg, missed or late menstrual cycle).  
If a subjec t is suspected to be pregnant before she receives IMP, the IMP administration must be 
withheld until the results of serum pregnancy tests are available. If the pregnancy is confirmed, the subject must not receive the IMP and must not be enrolled in the trial. If pregnancy is suspected while Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
41
CCI
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 42 of 66 
the subject is taking IMP, the IMP must be withheld immediately (if reasonable, taking into 
consideration any potential withdrawal risks) until the result of the pregnancy test is known. If pregnancy is confirmed, the IM P will be permanently discontinued in an appropriate manner (eg, dose 
tapering if necessary for subject safety) and the subject will be withdrawn from the trial.  
The investigator must immediately notify the sponsor of any pregnancy associated with IMP expo sure 
during the trial and for 30 days after the last dose of IMP for female subjects, and for 30 days after the last dose of IMP for partners of male subjects, and record the event on the IRE form and forward it to the sponsor. The sponsor will forward Pre gnancy Surveillance Form(s) for monitoring the outcome of 
the pregnancy.  
Protocol -required procedures for trial discontinuation and follow -up must be performed on the subject 
unless contraindicated by pregnancy (eg, x -ray studies). Other appropriate pregna ncy follow -up 
procedures should be considered, if indicated. In addition, the investigator must report to the sponsor, 
on appropriate Pregnancy Surveillance Form(s), follow -up information regarding the course of the 
pregnancy, including perinatal and neona tal outcome. Infants should be followed for a minimum of 6 
months from the date of birth, if consent is given to do so.  
9.9 FOLLOW -UP OF NON-SERIOUS ADVERSE EVENTS  
Nonserious AEs that are identified at any time during the trial must be recorded on the AE eCRF  with the 
current status (ongoing or resolved/recovered) noted. All nonserious events (that are not IREs) that are 
ongoing at the last scheduled contact will be recorded as ongoing on the eCRF. For any AE having been identified throughout the trial, during analysis, additional relevant medical history information may be 
requested by the sponsor to further ascertain causality (including, but not limited to, information such as risk related behavior, family history and occupation).  
9.10 FOLLOW -UP OF SERIOUS ADVERS E EVENTS  AND IMMEDIATELY REPORTABLE EVENTS  
This trial requires that participants  be actively monitored for SAEs and IREs for 7 -10 days after the last 
dose of IMP is administered.  
Serious AEs and nonserious IREs that are identified or ongoing at the last scheduled contact must be recorded as such on the AE eCRF page. If updated information (eg, resolved status) on SAE or IRE status 
becomes available after a participant’s last scheduled contact (up to last in -clinic visit for the entire 
trial), this mu st be reported to the sponsor according to the appropriate reporting procedures. The 
investigator will follow SAEs until the events are resolved, stabilized, or the participant is lost to follow  
up or has died. Resolution means that the participant has ret urned to the baseline state of health and  
stabilized means that the investigator does not expect any further improvement or worsening of the 
participant’s condition. The investigator will continue to report any significant follow -up information to  
the spon sor up to the point the event has resolved or stabilized, or the participant is lost to follow -up, or  
has died . Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
42
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 43 of 66 
9.11 FOLLOW -UP AND REPORTING OF SERIOUS ADVERSE EVENTS AND IMMEDIATELY REPORTABLE 
EVENTS OCCURRING AFTER LAST SCHEDULED CONTACT  
Any new SAEs or IREs reported to the investigator which occur after the last scheduled contact and are 
determined by the investigator to be reasonably associated with the use of the IMP, should be reported to the sponsor. This may include SAEs or IREs that are captured on foll ow-up telephone contact or at any 
other time point after the defined trial period. The investigator should follow SAEs or IREs identified 
after the defined trial period and continue to report any significant follow -up information to the sponsor 
until the e vents are  resolved , stabilized, or the participant  is lost to follow -up or has died.  
 DATA MANAGEMENT  
10.1 DATA COLLECTION PROCEDURES  
The results from the clinical assessments will be recorded in the source data file by the Investigator or 
their authorized designee and then captured in the case report forms (CRFs), unless otherwise  specified 
in the final protocol. Trained study personnel will be responsible for capturing the data from the 
observations, tests, and assessments specified in the protocol and in the source documents . Study 
personnel will transfer the data to the CRFs.  
The Investigator has ultimate responsibility for the collection and reporting of all data related to the clinical study and ensuring that the data are accurate, authentic/original, legib le, timely 
(contemporaneous), enduring, and available when required. Any corrections made to source documents 
must be clearly recorded, without obscuring the original values and be accompanied by the date of 
change, reason for change, and identification of the person making the change. CRF data will be verified 
against the source documents at the study site by appropriate staff. Instances of missing or unclear data will be discussed with the Investigator for resolution.  
10.2 PROTOCOL DEVIATIONS  / NONCOMPLIANCE  
Protocol deviations are defined as deviations from the study procedures as defined in this document, 
whether intention al or unintentional . Protocol deviations  that may affect the participant ’s rights, safety, 
or well- being and/or the completeness, accuracy,  and reliability of the data  must be reported to the IRB  
within 10 business days of becoming aware of the  deviation . 
Noncompliance is defined as any action or activity involving human subjects that fails to comply with  
applicable regulations.  Noncompliance that meets this definition must be reported to the IRB within 10 
business days of becoming aware of the noncompliance.  
10.3 DATA CAPTURE  
All data are collected from participant s using paper documents or an electronic data capture system. All 
applicable dat a, as specified in the protocol , will be transfe rred to the database or applicable Case 
Report Forms . Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
43
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 44 of 66 
10.3.1  Pre-screening Data  
Data will be collected for recruitment and screening purposes as stated within an Advarra IRB generic  
recruitment protocol. Unrelated to that recruitment protocol, pre -screening questionnaires will be 
attached to potential participant’s records on whether they qualify or are disqualified for this study. Pre -
Screening questionnaires utilized for this study  will be permanently attached to that potential 
volunteer’s record unless that information is requested to be removed by the participant.  
10.3.2  At-home Data Collection  
Electronic m essaging will be utilized for the delivery of a link  to a mobile device to collect  study data.  
This data will be collected utilizing an electronic survey . The platform  utilized for these messages will be 
eResearch , an IRB approved proprietary mobile research tool. Participants will be required to consent to 
use eResearch for daily at -home collection and be permitted to access the Survey functions for this 
protocol. The only other additional features available will be the standard publicly  available ability to 
update  and maintain their volunteer profile.  
10.3.3  Electronic Data Capture System  
All smoking behavioral and self- report measures will be captured using Medrio. All information collected 
within Medrio is compliant with 21 CFR 11 requirements.  
10.4 MISSING DATA 
Missing data will remain as missing, i.e., no attempt will be made to impute missing values .  
10.5 DATA HANDLING  
Data of all participant s enrolled including screening failures and AE /SAEs  during the study (from the time 
of informed consent to the end of the stu dy of the participant ) will be captured in the source 
documents.  For screening failures, o nly consent  date and reason for screen failure will be added to the 
CRFs. 
10.6 DATA VALIDATION  
Data of all participants enrolled including screening failures and AE/SAEs d uring the study (from the time 
of informed consent to the end of the study of the participant) will be captured in the source 
documents.  
10.7 DATABASE LOCK 
Upon completion of the trial, after data entry is complete, the data has been cleaned, and the principal 
investigator has reviewed and provided approval, the database will be locked, and final write access will 
be removed.  Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
44
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 45 of 66 
 PLANNED STATISTICAL METHODS  
All data measures (e.g., withdrawal symptoms questionnaires, smoking history, self -report daily smoking 
messag es, etc.) are captured initially using paper or an electronic data capture system. Verified data files 
will be analyzed using SAS (SAS Institute, Cary NC).  
11.1 SAMPLE SIZE ESTIMATION  
 
 
 
 
 
 
 
 
 
 
 
 
11.2 STATISTICAL METHODS  
The estimation of the four -week continuous smoking ab stinence rate at 6 weeks post target quit date is 
around 50% and  30% of  treated individuals experiencing nausea from varenicline treatment based on 
the historical studies .2  The smoking abstinence rate during weeks 4-7 will be calculated with 90% 
binomial confidence intervals , and t he incidence rate of nausea will be tabulated , which will be 
compared with the thresholds established for efficacy and tolerability.  
11.3 OUTCOMES  
In general, descriptive statistics  will be provided  for all efficacy and safety outcomes when  applicable. 
Details will be provided in statistical analysis plan (SAP).  
11.3.1  Smoking Abstinence  
Complete abstinence from combustible cigarette use at each time point will be defined by a self- report 
of no cigarette smoking (not even a puff) since the prior session, confirmed by an expired air CO reading 
of less than 5 ppm. The primary outcome will be  four -week continuous smoking abstinence during 
weeks 4-7. An intent -to-treat approach will be taken in which any participants lost to follow -up after 
receiving the investigational product, or who have smoked during weeks 4-7 will be counted as non -
abstinent.  
11.3.2  Inciden ce of Nausea  
A secondary outcome measure will be the incidence of nausea at any timepoint after drug administration begins . Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
45
CCI
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 46 of 66 
 ETHICS AND REGULATIONS  
12.1 IRB APPROVAL  
Prior to the start of the study, the clinical study protocol, together with its assoc iated documents 
(informed consent form [ICF], questionnaires, subject recruitment materials [e.g., advertisements, 
phone screening script], written information to be provided to the subjects, Investigators’ Brochure, the 
Investigator’s and designee’s curriculum vitae and/or other evidence of qualifications and any other documents requested by an Institutional Review Board [IRB], will be submitted for review and approval.  
Any change to the protocol must be submitted to the IRB for review and approval before  
implementation. A protocol change intended to eliminate an apparent immediate hazard to participant s 
may be implemented immediately provided the reviewing IRB are notified within 10 working days.  
12.2 INVESTIGATIONAL NEW DRUG APPLICATION  
An Investigational New  Drug (IND) application has been submitted to the FDA  (IND 155242 ) for the use 
of centanafadine.  
12.3 GCP  AND REGULATORY REQUIREMENTS  
This study will be conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Clinical Practice and applicable regulatory requirements. The study must be conducted in accordance with the regulations of the United States Food and Drug Administration (FDA) as described in 21 CFR 50 and 56, applicable laws and the IRB 
requirements.  
12.4 PARTICIPANT  INFORMATION AND CONSENT  
It is the responsibility of the investigator to provide each participant  with full and adequate verbal and 
written information using the IRB -approved informed consent form (ICF) , including the objective and 
procedures of the study and the possible risks involved before inclusion in the study. Informed consent 
must be obtained prior to performing any study -related procedures.  
The signed and per sonally dated original and completed ICF(s) must be kept by the Investigator and filed 
in the Investigator study file at the site or with the participant ’s files and a copy must be given to the 
participant . The participant  will be informed that if they  discontinue from the study, the data collected 
until the point of discontinuation will be maintained as part of the study data  and the samples 
collected prior to discontinuation will be analyzed, unless they  refuse in writing.  
12.5 AMENDMENT TO INFORMED CONSENT FORM 
If a protocol amendment is required, an amendment may be required to the ICF. If revision of the ICF is 
necessary, the Investigator or designee will ensure that the documents have been reviewed and 
approved by the IRB before participant s are informed and sign the amended ICF (including date and 
time).  Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
46
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 47 of 66 
 ADMINISTRATIVE CONSIDERATIONS  
13.1 PARTICIPANT  CONFIDENTIALITY  
All information obtained during the conduct of the study with respect to the participant s' state of health 
will be regarded as confidential. A statement to this effect will be written in the information provided to 
the participant . An agreement to disclose  any such information will be obtained from the participant  in 
writing and signed by the participant , in compliance with all local and national data protection and 
privacy legislation.  
Study records that identify participant s will be kept confidential as required by law. Except when 
required by law, participant s will not be identified by name, social security number, address, telephone 
number, or any other direct personal identifier in study records disclosed outside of Rose Research 
Center. For records dis closed outside of Rose Research Center, participant s will be assigned a unique 
code number. The key to the code will be kept separate from the locked file where the study records are stored.  
13.2 RECORDS RETENTION  
13.2.1  File Management at the Trial Site  
The investiga tor will ensure that the trial site file is maintained in accordance with applicable ICH GCP 
guidance and as required by applicable local regulations. The investigator/institution will take measures to prevent accidental or premature destruction of these d ocuments.   
13.2.2  Records Retention at the Trial Site  
Food and Drug Administration regulations require all investigators participating in clinical drug trials to maintain detailed clinical data for one of the following periods:  
• A period of at least 2 years after the date on which a New Drug Application is approved by the 
FDA;  
• A period of 2 years after the sponsor has notified the FDA that investigation with this drug is discontinued.  
The investigator must not dispose of any records relevant to this trial without either (1) written 
permission from the sponsor or (2) provision of an opportunity for the sponsor to collect such records. 
The investigator will be responsible to maintain adequate and accurate electronic or hard copy source 
documents of all observ ations and data generated during this trial including any data clarification forms 
received from the sponsor. Such documentation is subject to inspection by the sponsor and relevant regulatory authorities. If the investigator withdraws from the trial (eg, due to relocation or retirement), 
all trial related records should be transferred to a mutually agreed upon designee within a sponsor-
specified timeframe. Notice of such transfer will be given to the sponsor in writing.  
13.3 PUBLICATION AUTHORSHIP REQUIREMENTS  
Authorship for any Otsuka -sponsored publications resulting from the conduct of this trial will be based 
on International Committee of Medical Journal Editors (ICMJE) authorship criteria Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
47
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 48 of 66 
(http://www.icmje.org/recommendations). According to ICMJE guidelines,  one may be considered an 
author only if the following criteria are met:  
• Substantial contributions to the conception or design of the work; or the acquisition, analysis, 
or interpretation of data for the work; AND  
• Drafting the work or revising it criticall y for important intellectual content; AND  
• Final approval of the version to be published; AND  
• Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.  
All authors must meet the above criteria, and all who qualify for authorship based on the above criteria 
should be listed as authors.  
Investigators or other trial subjects who do not qualify for authorship may be acknowledged in publications resulting from the trial. By agreeing to participate in the trial, investigators or other trial 
subjects consent to such acknowledgement in any publications resulting from its conduct.  
  Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
48
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 49 of 66 
 REFERENCES  
1.  Otsuka Pharmaceutical. Centanafadine (EB- 1020) Investigator’s Brochure. In: ; 2020.  
2.  Reus VI, Obach RS, Coe JW, et al. Varenicline: new treatment with efficacy in smoking cessation. 
Drugs Today Barc Spain 1998 . 2007;43(2):65- 75. doi:10.1358/dot.2007.43.2.1069956  
3.  Jamal A. Current Cigarette Smoking Among Adults — United States, 2005 –2015. MMWR Morb 
Mortal Wkly Rep . 2016;65. doi:10.15585/mmwr.mm6544a2 
4.  Carter BD, Abnet CC, Feskanich D, et al. Smoking and Mortality — Beyond Established Causes. N 
Engl J Med. 2015;372(7):631 -640. doi:10.1056/NEJMsa1407211  
5.  Xu X, Bishop EE, Kennedy SM, Simpson SA, Pechacek TF. Annual healthcare spending attributable to cigarette smoking: an  update. Am J Prev Med . 2015;48(3):326 -333. 
doi:10.1016/j.amepre.2014.10.012 
6.  Tobacco Use and Dependence Guideline Panel. Table 6.26 Meta -analysis (2008): Effectiveness and 
abstinence rates for various medications and medication combinations compared to  placebo at 6 -
months postquit (n = 83 studies)a. In: Treating Tobacco Use and Dependence: 2008 Update.  US 
Department of Health and Human Services; 2008.  
7.  Harmey D, Griffin PR, Kenny PJ. Development of Novel Pharmacotherapeutics for Tobacco Dependence: P rogress and Future Directions. Nicotine Tob Res . 2012;14(11):1300- 1318. 
doi:10.1093/ntr/nts201 
8.  Halperin AC, McAfee TA, Jack LM, et al. Impact of symptoms experienced by varenicline users on tobacco treatment in a real world setting. J Subst Abuse Treat . 2009;36(4):428 -434. 
doi:10.1016/j.jsat.2008.09.001  
9.  Cahill K, Stevens S, Lancaster T. Pharmacological Treatments for Smoking Cessation. JAMA . 
2014;311(2):193. doi:10.1001/jama.2013.283787  
10.  Babb S, Malarcher A, Schauer G, Asman K, Jamal A. Quitting  smoking among adults — United States, 
2000– 2015. MMWR Morb Mortal Wkly Rep . 2017;65(52):1457- 1464. 
doi:http://dx.doi.org/10.15585/mmwr.mm6552a1external icon  
11.  Elrashidi MY, Ebbert JO. Emerging drugs for the treatment of tobacco dependence: 2014 update.  
Expert Opin Emerg Drugs . 2014;19(2):243- 260. doi:10.1517/14728214.2014.899580  
12.  Coe JW, Brooks PR, Vetelino MG, et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem . 2005;48(10):3474- 3477. doi:10.1021/jm050069n  
13.  Jackson SE, McGowan JA, Ubhi HK, et al. Modelling continuous abstinence rates over time from clinical trials of pharmacological interventions for smoking cessation. Addiction. 2019;114(5):787 -
797. doi:10.1111/add.14549 
14.  Hays JT, Ebbert JO, Sood A. Efficacy and safety of varenicline for smoking cessation. Am J Med . 
2008;121(4 Suppl 1):S32- 42. doi:10.1016/j.amjmed.2008.01.017  Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
49
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 50 of 66 
15.  CHANTIX® (varenicline tartrate) | Pfizer Medical Information - US. Accessed October 31, 2017. 
https://www.pfize rmedicalinformation.com/en -us/chantix  
16.  Swan GE, Javitz HS, Jack LM, et al. Varenicline for Smoking Cessation: Nausea Severity and Variation 
in Nicotinic Receptor Genes. Pharmacogenomics J. 2012;12(4):349 -358. doi:10.1038/tpj.2011.19  
17.  Rose JE, Mukhi n AG, Lokitz SJ, et al. Kinetics of brain nicotine accumulation in dependent and 
nondependent smokers assessed with PET and cigarettes containing 11C -nicotine. Proc Natl Acad 
Sci. 2010;107(11):5190 -5195. doi:10.1073/pnas.0909184107 
18.  Jiloha R. Biological basis of tobacco addiction: Implications for smoking -cessation treatment. Indian J 
Psychiatry . 2010;52(4):301. doi:10.4103/0019- 5545.74303 
19.  Bruijnzeel AW. Tobacco addiction and the dysregulation of brain stress systems. Neurosci Biobehav 
Rev. 2012;36(5):1418- 1441. doi:10.1016/j.neubiorev.2012.02.015 
20.  Toll BA, O’Malley SS, McKee SA, Salovey P, Krishnan -Sarin S. Confirmatory Factor Analysis of the 
Minnesota Nicotine Withdrawal Scale. Psychol Addict Behav J Soc Psychol Addict Behav . 
2007;21(2):216 -225. doi:10.1037/0893 -164X.21.2.216 
21.  Wigal SB, Wigal T, Hobart M, et al. Safety and Efficacy of Centanafadine Sustained -Release in Adults 
With Attention -Deficit Hyperactivity Disorder: Results of Phase 2 Studies. Neuropsychiatr Dis Treat . 
2020;16:1411- 1426. doi:10.2147/NDT.S242084  
22.  Wilkes S. The use of bupropion SR in cigarette smoking cessation. Int J Chron Obstruct Pulmon Dis . 
2008;3(1):45- 53. 
23.  Bymaster FP, Golembiowska K, Kowalska M, Choi YK, Tarazi FI. Pharmacological characterization of the n orepinephrine and dopamine reuptake inhibitor EB -1020: Implications for treatment of 
attention -deficit hyperactivity disorder. Synapse . 2012;66(6):522 -532. 
doi:https://doi.org/10.1002/syn.21538  
24.  Nilsson M, Suryawanshi S, Gassmann- Mayer C, Dubrava S, McSorley P, Jiang K. Columbia– Suicide 
Severity Rating Scale Scoring and Data Analysis Guide. Published online February 2013. https://cssrs.columbia.edu/wp- content/uploads/ScoringandDataAnalysisGuide -for-Clinical-Trials -
1.pdf  
25.  Lee YY, Khoo S,  Morris T, et al. A mixed -method study of the efficacy of physical activity consultation 
as an adjunct to standard smoking cessation treatment among male smokers in Malaysia. SpringerPlus . 2016;5(1):2012. doi:10.1186/s40064- 016-3675 -2 
26.  Virdis A, Giannarelli C, Neves MF, Taddei S, Ghiadoni L. Cigarette smoking and hypertension. Curr Pharm Des . 2010;16(23):2518- 2525. doi:10.2174/138161210792062920 
27.  New ACC/AHA High Blood Pressure Guidelines Lower Definition of Hypertension. American Co llege 
of Cardiology. Accessed April 19, 2021. http%3a%2f%2fwww.acc.org%2flatest -in-
cardiology%2farticles%2f2017%2f11%2f08%2f11%2f47%2fmon -5pm -bp-guideline -aha-2017  Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
50
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 51 of 66 
28.  Oparil S, Acelajado MC, Bakris GL, et al. Hypertension. Nat Rev Dis Primer . 2018;4:1801 4. 
doi:10.1038/nrdp.2018.14  
29.  Food Drug Administration Center for Drugs Evaluation Research. Guidance Document: Assessment 
of Abuse Potential of Drugs. Published online 2017.  
 
  Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
51
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 58 of 66 
Appendix 2 – Fagerstr öm Test for Nicotine Dependence (FTND)  
 
 
  
Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
58
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 59 of 66 
Appendix 3 – Smoking History  
 
 
  
Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
59
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 60 of 66 
Appendix 4 – Other Nicotine Use Questionnaire  
  
Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
60
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 61 of 66 
Appendix 5 – M odified Cigarette Evaluation Questionnaire  – Extended  (mCEQE ) 
 
Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
61
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 62 of 66 
 
  
Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
62
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 63 of 66 
Appendix 6 – Reasons to Smoke  
  
  
Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
63
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 64 of 66 
Appendix 7 – Shiffman Jarvik Withdrawal Scale  
 
  
Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
64
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 65 of 66 
 
 
 
 
Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
65
Rose Research Center, LLC  Version 3.0 / 16 Aug 2021  Confidential - Page 66 of 66 
Appendix 8 – Minnesota Nicotine Withdrawal Scale  
 
 
Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
66
This page is a manifestation of an electronically captured signature
SIGNATURE PAGE
Document Name: 405-201-00055 Protocol Amendment 1
Document Number: 
Document Version: 
Signed by Meaning of Signature Server Date
(dd-MMM-
yyyy hh:min) -
UTC timezone
Biostatistics Approval 17-Aug-2021
19:37:24
Clinical Approval 17-Aug-2021
18:01:55Synopsis Clinical Study Report 405-201-00055 4.1 Protocol and Protocol Amendments
Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
68
PPD
PPD
CCI
CCI